Patent Application
20110150841
Bacterial infection and abnormal cell growth are causative factors in a variety of disease states and environmental contamination. Thus, developing new reagents and methods to inhibit bacterial infection and abnormal cell growth are of substantial importance.
In a first aspect, the present invention provides substantially purified type VI secretion exported (Tse) proteins, selected from the group consisting of Tse1, Tse2, and Tse3.
In a second aspect, the present invention provides substantially purified nucleic acids encoding the Tse protein-transduction domain conjugate of any embodiment of the invention.
In a third aspect, the present invention provides a vector comprising the substantially purified nucleic acid of any embodiment of the second aspect of the invention, wherein the substantially purified nucleic acid is operatively linked to a regulatory sequence.
In a fourth aspect, the present invention provides host cells tcomprising the recombinant expression vector of any embodiment of the third aspect of the invention.
In a fifth aspect, the present invention provides pharmaceutical compositions comprising the substantially purified Tse1, Tse2, and/or Tse3 protein of any embodiment of the invention; and
(b) a pharmaceutically acceptable carrier.
In a sixth aspect, the invention provides host cells comprising,
(a) a plurality of genes encoding proteins capable of forming a type 6 secretion system (T6SS); and
(b) a recombinant gene encoding a therapeutic polypeptide that can be secreted by the recombinant T6SS in the recombinant cell, wherein the recombinant gene is operatively linked to a regulatory sequence. In one embodiment, the recombinant gene encodes a fusion polypeptide of (a) a therapeutic polypeptide selected from the group consisting of bactericidal proteins group HA phospholipase A2, bactericidal/permeability-increasing protein, human peptidoglycan recognition proteins 3 and 4 (PGLYRP3 and PGLYRP4), Tse1, Tse2, Tse3, or other native T6SS substrates, or functional equivalents thereof; and (b) one or both of a VgrG polypeptide and a Hcp polypeptide. Thus, the present invention also provides novel fusion polypeptides comprising (a) a therapeutic polypeptide selected from the group consisting of bactericidal proteins group IIA phospholipase A2, bactericidal/permeability-increasing protein, human peptidoglycan recognition proteins 3 and 4 (PGLYRP3 and PGLYRP4), Tse1, Tse2, Tse3, or other native T6SS substrates, or functional equivalents thereof; and (b) one or both of a VgrG polypeptide and a Hcp polypeptide, and novel genes encoding such polypeptides.
In a seventh aspect, the present invention provides pharmaceutical compositions comprising (a) the recombinant host cells of the sixth aspect of the invention; and (b) a pharmaceutically acceptable carrier.
In an eighth aspect, the present invention provides an anti-bacterial composition comprising the recombinant host cell or polypeptide of any embodiment disclosed herein adhered to a substrate.
In a ninth aspect, the present invention provides methods for inhibiting bacterial growth, comprising contacting bacteria to be inhibited with an amount of the host cells of any embodiment of the invention or the substantially purified polypeptide of any embodiment of the invention effective to inhibit bacterial growth.
In a tenth aspect, the present invention provides methods for inhibiting eukaryotic growth, comprising contacting eukaryotic cells to be inhibited with an amount of the substantially purified Tse protein-transduction domain conjugates of the first aspect of the invention effective to inhibit eukaryotic cell growth.
In an eleventh aspect, the present invention provides recombinant vectors, comprising a first gene coding for Tse1 or Tse3, of functional equivalents thereof, wherein the first gene is operatively linked to a heterologous regulatory sequence.
In a twelfth aspect, the present invention provides recombinant host cells comprising the recombinant vector of any embodiment or combination of embodiments of the eleventh aspect of the invention.
In a thirteenth aspect, the present invention provides methods for selectable cloning, comprising culturing the recombinant host cell of any embodiment of the twelfth aspect of the invention under conditions suitable for expression of Tse1 or Tse3 from the recombinant vector if no insert is present, and selecting those cells that grow as comprising recombinant vectors with the insert cloned into the expression vector.
In a fourteenth aspect, the present invention provides methods for producing a cloning vector that lacks an insert, comprising culturing the recombinant host cell of any embodiment of the twelfth aspect of the invention under conditions suitable for vector replication and expression of Tse1 or Tse3, wherein the recombinant host cells further express a Tse1 or Tse3 antidote, and isolating vector from the host cells.
All references cited are herein incorporated by reference in their entirety. Within this application, unless otherwise stated, the techniques utilized may be found in any of several well-known references such as: Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, Calif.), “Guide to Protein Purification” in Methods in Enzymology (M. P. Deutshcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis, et al. 1990. Academic Press, San Diego, Calif.), Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed. (R. I. Freshney. 1987. Liss, Inc. New York, N.Y.), Gene Transfer and Expression Protocols, pp. 109-128, ed. E. J. Murray, The Humana Press Inc., Clifton, N.J.), and the Ambion 1998 Catalog (Ambion, Austin, Tex.).
As used herein, the singular forms “a”, “an” and “the” include plural referents unless the context clearly dictates otherwise. “And” as used herein is interchangeably used with “or” unless expressly stated otherwise.
All embodiments of any aspect of the invention can be used in combination, unless the context clearly dictates otherwise.
In a first aspect, the present invention provides substantially purified type VI secretion exported (Tse) proteins, selected from the group consisting of Tse1, Tse2, and Tse3. As shown in the examples that follow, Tse1, Tse2, or Tse2 are Pseudomonas aeruginosa proteins that are toxic to a broad spectrum of prokaryotic and eukaryotic cells, and thus can be used, for example, as therapeutics to destroy deleterious cells of interest.
As used herein, “substantially purified” means that the polypeptide has been separated from its in vivo cellular environments. It is further preferred that the isolated polypeptides are also substantially free of gel agents, such as polyacrylamide, agarose, and chromatography reagents.
In one preferred embodiment, the Tse is Tse2 and comprises or consists of the P. aeruginosa amino acid sequence according to SEQ ID NO:2. Closely related Tse2 proteins are present in other P. aeruginosa strains, with variable positions noted in SEQ ID NOS:4. Thus, in another preferred embodiment, Tse2 comprises or consists of an amino acid sequence according to SEQ ID NO:4.
As used herein, “Tse2” includes functional equivalents (truncations, mutants, etc.) thereof, wherein such equivalents maintain cytotoxic activity as described herein. Methods for identifying such functional equivalents are disclosed herein and a variety of such functional equivalents are disclosed. The inventors have discovered that residues 1-6 and 156-158 of Tse2 are not required for toxicity (See Table 1 below). Thus, in another embodiment, the first gene comprises a nucleotide sequence that can encode an amino acid sequence according to SEQ ID NO:5 or SEQ ID NO:6.
The inventors have further identified a series of Tse2 mutant polypeptides that retain toxicity. Specifically, the inventors have shown (see below) that mutations at positions 9, 10, 60, 119, 129, 130, 139, 140, 149, and 150 of SEQ ID NO:2 can be tolerated while retaining toxicity (See Table 2 below). Thus, in another embodiment, the first gene encodes a mutant Tse2 polypeptide that differs from the amino acid sequence of SEQ ID NO:2 by an amino acid substitution at one or more of amino acid residues 9, 10, 60, 119, 129, 130, 139, 140, 149, and 150, and is optionally deleted for one or more of resides 1-6 and one or more of residues 156-158. In another embodiment, the first gene encodes a mutant Tse2 polypeptide that includes one or more amino acid substitutions selected from the group consisting of S9A. L10A, R60A, Q119A, K129A, P129A, Q139A, L139A, R149A, and R150A. In a further preferred embodiment, the first gene comprises a nucleotide sequence that can encode an amino acid sequence according to SEQ ID NO:7 or SEQ ID NO:8.
In another preferred embodiment, the Tse is Tse1 and comprises or consists of the amino acid sequence according to SEQ ID NO:10. In a further preferred embodiment, the Tse is Tse3 and comprises or consists of the amino acid sequence according to SEQ ID NO:12.
As used herein, “Tse1” and “Tse3” includes functional equivalents (truncations, mutants, etc.) thereof, wherein such equivalents maintain cytotoxic activity as described herein. Methods for identifying such functional equivalents are disclosed herein and a variety of such functional equivalents are disclosed.
In a further preferred embodiment of any embodiment disclosed above, the substantially purified Tse protein comprises a Tse-transduction domain conjugate. As disclosed below, the Tse proteins are toxic to cells (prokaryotic and eukaryotic) when expressed intracellularly. As used herein, the term “transduction domain” means one or more amino acid sequence or any other molecule that promote the intracellular delivery of cargo that would otherwise fail to, or only minimally, traverse the cell membrane. These domains can be linked, for example, to other polypeptides to direct movement of the linked polypeptide across cell membranes. Thus, the Tse-transduction fusion proteins can be used to directly administer the Tse toxins to deleterious cells. A wide variety of such transduction domains are known in the art, including but not limited to GRKKRRQRRRPPQ (SEQ ID NO:13) RQIKIWFQNRRMKWKK (SEQ ID NO: 14) RRMKWKK (SEQ ID NO: 15) RGGRLSYSRRRFSTSTGR (SEQ ID NO: 16) RRLSYSRRRF (SEQ ID NO: 17) RGGRLAYLRRRWAVLGR (SEQ ID NO: 18) RRRRRRRR. (SEQ ID NO: 19) YGRKKRRQRRR (SEQ ID NO: 20), ILLPLLLLP (SEQ ID NO: 21), RQLKIWFQNRRMKWKK (SEQ ID NO: 22), RKKRRQRRR (SEQ ID NO: 23), YARAAARQARA (SEQ ID NO: 24), RRQRRTSKLMKR (SEQ ID NO: 25), AAVLLPVLLAAR (SEQ ID NO: 26), RRRRRRRRR (SEQ ID NO: 27), SGWFRRWKK (SEQ ID NO: 28), RQIKIWFQNRRMKWKK (SEQ ID NO: 29), (R)4-9 (SEQ ID NO: 30), GRKKRRQRRRPPQ (SEQ ID NO: 31), DAATATRGRSAASRPTERPRAPARSASRPRRPVE (SEQ ID NO: 32), GWTLNSAGYLLGLINLKALAALAKKIL (SEQ ID NO: 33), PLSSIFSRIGDP (SEQ ID NO: 34), AAVALLPAVLLALLAP (SEQ ID NO: 35), AAVLLPVLLAAP (SEQ ID NO: 36), VTVLALGALAGVGVG (SEQ ID NO: 37), GALFLGWLGAAGSTMGAWSQP (SEQ ID NO: 38), GWTLNSAGYLLGLINLKALAALAKKIL (SEQ ID NO: 39), KLALKLALKALKAALKLA ((SEQ ID NO: 40), KETWWETWWTEWSQPKKKRKV (SEQ ID NO: 41), KAFAKLAARLYRKAGC (SEQ ID NO: 42), KAFAKLAARLYRAAGC (SEQ ID NO: 43), AAFAKLAARLYRKAGC (SEQ ID NO: 44), KAFAALAARLYRKAGC (SEQ ID NO: 45), KAFAKLAAQLYRKAGC (SEQ ID NO: 46), GGGGYGRKKRRQRRR (SEQ ID NO: 47), and YGRKKRRQRRR (SEQ ID NO: 48).
In any of these embodiments, the substantially purified Tse protein-transduction domain conjugate preferably comprises the general formula X1-Tse-X2, wherein X1 and X2 independently comprise a transduction domain or are absent, with the proviso that at least one of X1 and X2 are present.
In another preferred embodiment that can be combined with any of the above embodiments, the Tse protein or Tse protein-transduction domain conjugate further comprises a cell targeting molecule. As used herein, a “cell targeting molecule” is a molecule, such as a polypeptide, that binds to a cell surface receptor, to facilitate cell specific targeting of the Tse protein. Any suitable cell targeting molecule can be used that is appropriate for a given purpose. In various non-limiting embodiments, the cell targeting molecule is selected from the group consisting of a tumor targeting molecule such as transferrin or folate; an amino acid sequence which consists of the amino acids arginine, followed by glycine and aspartate (also known as an RGD motif) for targeting epithelial and endothelial cells; glycoside or lectin-containing molecules to facilitate targeting of lectin expressing tumor cells, macrophages, hepatocytes and parenchymal cells; and a monoclonal antibody, or fragment thereof, which can bind to the chosen target cells, such as cancer cells of a desired target type.
In another embodiment, the Tse1 or Tse3 is a fusion protein that comprises a secretory signal sequence. The term “secretory signal sequence” or “signal sequence” are described, for example in U.S. Pat. No. 6,291,212 and U.S. Pat. No. 5,547,871, both of which are herein incorporated by reference in their entirety.
In a second aspect, the present invention provides substantially purified nucleic acids encoding the Tse protein-transduction domain conjugate of any embodiment of the invention. As used herein, a “nucleic acid” includes DNA, RNA, mRNA, cDNA, and analogs thereof, whether single stranded or double stranded.
As used herein, “substantially purified nucleic acids” are those that have been removed from their normal surrounding nucleic acid sequences. Such substantially purified nucleic acid sequences may comprise additional sequences useful for promoting expression and/or purification of the encoded protein, including but not limited to polyA sequences, modified Kozak sequences, and sequences encoding epitope tags, export signals, and secretory signals, nuclear localization signals, and plasma membrane localization signals.
In a third aspect, the present invention provides a vector comprising the substantially purified nucleic acid of any embodiment of the second aspect of the invention, wherein the substantially purified nucleic acid is operatively linked to a regulatory sequence. Any suitable vectors can be used, including nut not limited to plasmid and viral vectors.
Vectors, such as expression vectors and methods for their engineering and isolation are well known in the art (see, e.g., Maniatis et al., supra), or they can be obtained through a commercial vendor, e.g., Invitrogen (Carlsbad, Calif.), Promega (Madison, Wis.), and Statagene (La Jolla, Calif.) and modified as needed. Examples of commercially available expression vectors include pcDNA3 (Invitrogen), Gateway cloning technology (Life Technologies), and pCMV-Script (Stratagene). Vector components, regulatory nucleic acids, etc. are typically available from a commercial source or can be isolated from a natural source (e.g., animal tissue or microorganism) or prepared using a synthetic means such as PCR. The arrangement of the components can be any arrangement practically desired by one of ordinary skill in the art.
Vectors used in the present invention can be derived from viral genomes that yield virions or virus-like particles, which may or may not replicate independently as extrachromosomal elements. Virion particles containing the DNA for the high expression locus can be introduced into the host cells by infection. The viral vector may become integrated into the cellular genome. Examples of viral vectors for transformation of mammalian cells are SV40 vectors, and vectors based on papillomavirus, adenovirus, Epstein-Barr virus, vaccinia virus, and retroviruses, such as Rous sarcoma virus, or a mouse leukemia virus, such as Moloney murine leukemia virus. For mammalian cells, electroporation or viral-mediated introduction can be used.
As used herein, a regulatory nucleic acid is any sequence that regulates or affects (i) transcription, (ii) translation, and/or (iii) post-translational modifications, during expression of a gene operatively linked the regulatory nucleic acid, and which contains one or more “control elements” for regulating such activity. A regulatory nucleic acid and operatively linked gene need not derive from the same organism or cell type. The term “control element” of a regulatory nucleic acid is well known in the art (see, e.g., Goeddel, Gene Expression Technology, Methods in Enzymology 185, Academic Press, San Diego, Calif., 1990), and includes, e.g., transcriptional promoters, transcriptional enhancer elements, transcriptional termination signals, polyadenylation sequences (located 3′ to the translation stop codon), sequences for optimization of initiation of translation (located 5′ to the coding sequence), translation termination sequences, sequences that direct post-translational modification (e.g., glycosylation sites), all of which may be used to regulate the transcription and/or translation of a gene operatively linked to a regulatory sequence. It shall be appreciated by those skilled in the art that the selection of control elements of a regulatory nucleic acid will depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.
The term “promoter” includes any nucleic acid sequence sufficient to direct transcription in the host cell, including inducible promoters, repressible promoters and constitutive promoters. Exemplary promoters include bacterial, viral, mammalian and yeast promoters, as are well known in the art. Many such promoters, including inducible promoters, are commercially available from vendors including Life Technologies, System Biosciences, and Promega Biosciences. In one preferred embodiment, the substantially purified Tse1, 2, or 3 nucleic acid is operatively linked to a promoter element sufficient to render promoter-dependent controllable gene expression, for example, inducible by external signals or agents (adding/removing compounds from the growth media for the recombinant cells), or by altering culture conditions (temperature, pH, etc.). Exemplary inducible promoters are those that are alcohol-regulated, tetracycline-regulated, steroid-regulated, metal-regulated, pathogen-regulated, light-regulated, or temperature-regulated. For use in bacterial systems, many inducible promoters are known (Old and Primrose, 1994). Common examples include Plac (IPTG), Ptac (IPTG), lambdaPR (loss of CI repressor), lambdaPL (loss of CI repressor), Ptrc (IPTG), Ptrp (IAA). The inducing agent is shown in brackets after each promoter. Examples of inducible plant promoters include the root-specific ANRI promoter (Zhang and Forde (1998) Science 279:407) and the photosynthetic organ-specific RBCS promoter (Khoudi et al. (1997) Gene 197:343). Further exemplary inducible promoters include the Tet-system (Gossen and Bujard, PNAS USA 89: 5547-5551, 1992), the ecdysone system (No et al., PNAS USA 93: 3346-3351, 1996), the progesterone-system (Wang et al., Nat. Biotech 15: 239-243, 1997), and the rapamycin-system (Ye et al., Science 283:88-91, 1999), arabinose-inducible promoters, and rhamnose-inducible promoters.
In a fourth aspect, the present invention provides host cells comprising the recombinant expression vector of any embodiment of the third aspect of the invention, wherein the host cells can be either prokaryotic or eukaryotic. The cells can be transiently or stably transfected. Such transfection of expression vectors into prokaryotic and eukaryotic cells can be accomplished via any technique known in the art, including but not limited to standard bacterial transformations, calcium phosphate co-precipitation, electroporation, or liposome mediated-, DEAE dextran mediated-, polycationic mediated-, or viral mediated transfection. (See, for example, Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press; Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed. (R. I. Freshney. 1987. Liss, Inc. New York, N.Y.).
In a fifth aspect, the present invention provides pharmaceutical compositions comprising the substantially purified Tse1, Tse2, and/or Tse3 protein of any embodiment of the invention; and
(b) a pharmaceutically acceptable carrier.
For administration, the proteins are ordinarily combined with one or more adjuvants appropriate for the indicated route of administration. The proteins may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, stearic acid, talc, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulphuric acids, acacia, gelatin, sodium alginate, polyvinylpyrrolidine, dextran sulfate, heparin-containing gels, and/or polyvinyl alcohol, and tableted or encapsulated for conventional administration. Alternatively, the proteins may be dissolved in saline, water, polyethylene glycol, propylene glycol, carboxymethyl cellulose colloidal solutions, ethanol, corn oil, peanut oil, cottonseed oil, sesame oil, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well known in the pharmaceutical art. The carrier or diluent may include time delay material, such as glyceryl monostearate or glyceryl distearate alone or with a wax, or other materials well known in the art.
The proteins may be made up in a solid form (including granules, powders or suppositories) or in a liquid form (e.g., solutions, suspensions, or emulsions). The proteins may be applied in a variety of solutions. Suitable solutions for use in accordance with the invention are sterile, dissolve sufficient amounts of the polypeptides, and are not harmful for the proposed application.
In a sixth aspect, the invention provides host cells comprising,
(a) a plurality of genes encoding proteins capable of forming a type 6 secretion system (T6SS); and
(b) a recombinant gene encoding a therapeutic polypeptide that can be secreted by the recombinant T6SS in the recombinant cell, wherein the recombinant gene is operatively linked to a regulatory sequence.
As disclosed below, the inventor has discovered that T6SSs can be used to deliver polypeptide therapeutics to other bacteria, and thus can be used for targeting toxins (or other proteins/macromolecules) to bacteria.
The “host cells” can be any host cell capable of expressing T6SS endogenously or by recombinant means, and secreting the therapeutic polypeptide via the T6SS. Type VI secretion systems have been found in most genomes of proteobacteria, including animal, plant, human pathogens, as well as soil, environmental and marine bacteria. In one embodiment, the host cell is a bacterial cell and the T6SS is the endogenous T6SS expressed by that bacteria. In a preferred embodiment, the bacterial cell is a gram negative bacteria, including but not limited to P. fluorescens, Burkholderia that, P. putida, proteobacteria including but not limited to Escherichia coli, Salmonella, Shigella, and other Enterobacteriaceae, Pseudomonas, Moraxella, Helicobacter, Stenotrophomonas, Bdellovibrio, acetic acid bacteria, Legionella, Wolbachia, cyanobacteria, spirochaetes, green sulfur and green non-sulfur bacteria, Hemophilus influenzae, Klebsiella pneumoniae, Legionella pneumophila, Pseudomonas aeruginosa, Proteus mirabilis, Enterobacter cloacae, Serratia marcescens, Helicobacter pylori, Salmonella enteritidis, Salmonella typhi, Acinetobacter baumannii, Pseudomonas aeruginosa, Burkholderia cepacia, Burkholderia pseudomallei, Ralstonia picketti, Acinetobacter baumanii, Klebsiella pneuominiaw, Proteus mirabilis, Chromobacterium violaceum, Bordetella sp. (parapertussis, bronchiseptics, petrii), E. coli, Salmonella enterica, Shigella sonnei, Campylobacter concisus, Vibrio sp. (cholerae, parahaemolyticus, vulnificus), Aeromonas sp., Yersinia enterocolitica, and Acinebacter baumanii. In other embodiments, the host cell is a plant bacteria (ie: rhizobacteria, endophytic bacteria, Agrobacterium sp. (rhisogens, tumefaciens, vitis), Paracoccus denitrificans, or other bacteria such as Bacillus cereus, Xenorhabdus nematophilus, Micrococcus luteus, Staphylococcus, Xanthomas campestris, Francisella novicida, Rhodobacter sphaeroides, Acidovorax temperans, etc.
A number of T6SS-containing bacteria are known to be associated with human disease, and thus in a preferred embodiment where any of these bacterial types is the host cell, the host cells are attenuated to reduce/eliminate risks associated with use of the bacteria. In a further embodiment, the host cell is a recombinant host cell engineered to express a heterologous (not naturally occurring in the cell type) T6SS. As used herein, a “recombinant T6SS” includes at least 5 of the 13 conserved T6SS “core component” genes, exemplified by those disclosed in Schwarz et al PLoS Pathogens 2010: COG0542 (exemplified by ClpV as disclosed herein), COG3157 (exemplified by Hcp as disclosed herein), COG3455, COG3501 (exemplified by VgrG as disclosed herein), COG3515, COG3516 (exemplified by VipA as disclosed herein), COG3517 (exemplified by VipB as disclosed herein), COG3518, COG3519, COG3520, COG3521, COG3522, COG3523 (exemplified by IcmF as disclosed herein). Sequences and other information can be found, for example at the Genome Reviews web site (ftp://ftp.ebi.ac.uk/pub/databases/genome_reviews/). The recombinant T6SS can comprise or consist of 5, 6, 7, 8, 9, 10, 11, 12, or all 13 of the recited T6SS “core component” genes. In a preferred embodiment, COG3516 (exemplified by VipA protein) is one of the TG66 core component genes used to construct a recombinant T6SS; in further embodiments the TG66 core component genes used to construct a recombinant T6SS further comprise 1, 2, 3, 4, or all 5 of COG0542 (exemplified by ClpV as disclosed herein), COG3157 (exemplified by Hcp as disclosed herein), COG3501 (exemplified by VgrG as disclosed herein), COG3516 (exemplified by VipA as disclosed herein), and COG3517 (exemplified by VipB as disclosed herein).
Exemplary references that describe the entire T6SS for a number of different organisms include Boyer F and Attree I BMC Genomics. 2009 Mar. 12; 10:104 and Schwarz, et al. (2010) PLoS Pathog 6(8): e1001068. doi:10.1371/journal.ppat.1001068).
Existing bacteria or recombinat host cells engineered to express a heterologous T6SS can be tested for T6SS activity by, for example, hemolysin co-regulated protein (Hcp) and/or VgrG secretion. In another embodiment, a functional T6SS that targets a bacterial cell can be detected by comparing the fitness of the bacterium the T6SS is expressed in against a target bacterium relative to the fitness against that target bacterium if the T6SS is disabled by the removal of one of the essential genes (including icmF (also called tssM) or clpV).
The host cells of this aspect of the invention comprise a recombinant gene encoding a therapeutic polypeptide. The therapeutic polypeptide can be any polypeptide that can be secreted by the T6SS in the recombinant cells and provide a therapeutic benefit. As disclosed below, the inventors have found that the T6SS pathway is of general significance to interbacterial interactions in polymicrobial human diseases and the environment, and thus the host cells of this aspect of the invention can be used for targeting toxins (or other proteins/macromolecules) to bacteria involved in disease (human, animal, plant) and environmental contamination. In one embodiment, the therapeutic polypeptide is toxic to bacteria, including but not limited to bactericidal proteins group IIA phospholipase A2, bactericidal/permeability-increasing protein, human peptidoglycan recognition proteins 3 and 4 (PGLYRP3 and PGLYRP4), Tse1, Tse2, Tse3, or other native T6SS substrates, or functional equivalents thereof. In a preferred embodiment, the therapeutic polypeptide comprises Tse1, Tse2, Tse3, or functional equivalents thereof; all embodiments of Tse1, Tse2, and Tse3 disclosed herein can be used in this aspect of the invention.
Regulatory sequences to direct expression of the recombinant gene can be any suitable for use in the host cell and that are appropriate for a given use. Regulatory sequences are discussed above, and this sixth aspect includes all embodiments of the regulatory sequences and control elements disclosed herein.
In a further preferred embodiment, the recombinant gene encoding a therapeutic polypeptide encodes a fusion polypeptide of the therapeutic polypeptide and one or both of a VgrG polypeptide and a Hcp polypeptide. Bacteria expressing T6SSs have been demonstrated to secrete Hcp and VgrG, and have been shown to secrete variants of these conserved proteins that include additional peptide domains (Blondel et al., BMC Genomics 2009, 10:354). Thus, in this embodiment the host cells are engineered such that a VgrG polypeptide or a Hcp polypeptide is utilized to secrete the therapeutic polypeptide through the T6SS to, for example, inhibit bacteria involved in disease (human, animal, plant) or environmental contamination. In one preferred embodiment, the VgrG polypeptide and/or the Hcp polypeptide used are natural substrates of the T6SS being used, in that they are derived from the same organism as the T6SS is derived from. In one exemplary embodiment, the Hcp polypeptide comprises or consists of a P. aeruginosa Hcp polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:50, or functional fragment thereof. In another exemplary embodiment, the VgrG polypeptide comprises or consists of a P. aeruginosa VgrG polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:52, or functional fragment thereof.
Thus, the present invention also provides novel fusion polypeptides comprising (a) a therapeutic polypeptide selected from the group consisting of bactericidal proteins group HA phospholipase A2, bactericidal/permeability-increasing protein, human peptidoglycan recognition proteins 3 and 4 (PGLYRP3 and PGLYRP4), Tse1, Tse2, Tse3, or other native T6SS substrates, or functional equivalents thereof; and (b) one or both of a VgrG polypeptide and a Hcp polypeptide, and novel genes encoding such polypeptides. In a preferred embodiment, the therapeutic polypeptide comprises Tse1, Tse2, Tse3, or functional equivalents thereof; all embodiments of Tse1, Tse2, and Tse3 disclosed herein can be used in this aspect of the invention. The recombinant genes as described in this aspect can be used, for example, in vectors for transfection to create the host cells of the sixth aspect of the invention. The invention further comprises novel fusion proteins comprising (a) a therapeutic polypeptide selected from the group consisting of bactericidal proteins group HA phospholipase A2, bactericidal/permeability-increasing protein, human peptidoglycan recognition proteins 3 and 4 (PGLYRP3 and PGLYRP4), Tse1, Tse2, Tse3, or other native T6SS substrates, or functional equivalents thereof; and (b) one or both of a VgrG polypeptide and a Hcp polypeptide. In a preferred embodiment, the therapeutic polypeptide comprises Tse1, Tse2, Tse3, or functional equivalents thereof; all embodiments of Tse1, Tse2, and Tse3 disclosed herein can be used in this aspect of the invention.
In a seventh aspect, the present invention provides pharmaceutical compositions comprising (a) the recombinant host cells of the sixth aspect of the invention; and (b) a pharmaceutically acceptable carrier. Any suitable carrier can be used for a given application. The compositions of the invention may be used for in vivo applications, such as the therapeutic aspects of the invention disclosed below. For in vivo use, the composition may be formulated for delivery via standard administrative routes, or may be administered, for example, as part of a fermented food product (“probiotic”), such as yogurt, beverage, or a dietary supplement.
In an eighth aspect, the present invention provides an anti-bacterial composition comprising the recombinant host cell or polypeptide of any embodiment disclosed above adhered to a substrate. This embodiment can be any type of composition that permits cell-cell contact between the cells of the composition and bacterial cells to be eliminated. Such compositions include, but are not limited to, liquids, soaps, wipes, powders, etc. The anti-bacterial composition can contain any other anti-bacterial or other components as suitable for a given purpose.
In a ninth aspect, the present invention provides methods for inhibiting bacterial growth, comprising contacting bacteria to be inhibited with an amount of the host cells of any embodiment of the invention or the substantially purified polypeptide of any embodiment of the invention effective to inhibit bacterial growth. As disclosed below, the inventors have found that the T6SS pathway is of general significance to interbacterial interactions in polymicrobial human diseases and the environment, and thus the host cells of the invention can be used for targeting toxins (or other proteins/macromolecules) to bacteria involved in disease (human, animal, plant) and environmental contamination. The inventors have further identified three different toxins (Tse1, Tse2, and Tse3) that are toxic to bacteria, and thus these toxins can be administered to inhibit bacterial growth.
As used herein, “inhibiting bacterial growth” includes one or more of slowing the growth rate of bacteria, minimizing further bacterial replication, and killing of existing bacteria.
In one preferred embodiment, the method comprises in vivo administration of the composition or polypeptide to a subject with a bacterial infection. The “subject” can be a human, animal (cattle, dogs, cats, sheep, chickens, etc.), or plant The bacterial infection can be any one caused by bacteria susceptible to growth inhibition by the therapeutic. The methods can be used for treatment of diseases linked to bacterial infection, including but not limited to gingivitis, middle ear infections, myocarditis, pneumonia, urinary tract/GI infections, and infections associated with burn victims, cystic fibrosis, and plant bacterial infections. In a preferred embodiment, the bacteria to be inhibited are present in a biofilm. A biofilm is an aggregate of microorganisms in which cells adhere to each other and/or to a surface. Nearly every species of microorganism, not only bacteria and archaea, have mechanisms by which they can adhere to surfaces and to each other. Biofilms will form on virtually every non-shedding surface in a non-sterile aqueous environment.
In another preferred embodiment the method comprises administration of the composition or the polypeptide to a surface to be treated. Any surface that is subject to bacterial contamination (such as biofilm formation) can be contacted, including but not limited to medical devices (ex: catheters, contact lens, heart valves, joint prostheses, intrauterine devices, etc.) countertops, door handles, sinks, faucets, showers, water and sewage pipes, floors, pipelines (ex: oil and gas pipelines), boat hulls, teeth, infected skin wounds, plants,
In a tenth aspect, the present invention provides methods for inhibiting eukaryotic growth, comprising contacting eukaryotic cells to be inhibited with an amount of the substantially purified Tse protein-transduction domain conjugates of the first aspect of the invention effective to inhibit eukaryotic cell growth. As disclosed below, the Tse proteins are toxic to cells (prokaryotic and eukaryotic) when expressed intracellularly. Transduction domains can be linked, for example, to other polypeptides to direct movement of the linked polypeptide across cell membranes. Thus, the Tse-transduction fusion proteins can be used to directly administer the Tse toxins to deleterious cells.
In a preferred embodiment, the eukaryotic cell is a mammalian cell; more preferably a human cell. The methods can be used to treat any diseases associated with undesired cell growth, including but not limited to, cancer, diabetic retinopathy, psoriasis, and rheumatoid arthritis. The substantially purified polypeptides may be used alone or in combination with any other suitable therapeutics for inhibiting eukaryotic cell growth.
In practicing these various methods of the invention, the amount or dosage range of the polypeptides or pharmaceutical compositions employed is one that effectively inhibits bacterial or eukaryotic cell growth. Such an inhibiting amount of the polypeptides or host cells will vary depending on the disorder being treated and other factors, and can be determined by one of skill in the art.
In an eleventh aspect, the present invention provides recombinant vectors, comprising a first gene coding for Tse1 or Tse3, of functional equivalents thereof, wherein the first gene is operatively linked to a heterologous regulatory sequence. As disclosed above, Tse1 and Tse3 are toxic to a broad spectrum of prokaryotic and eukaryotic cells. Thus, Tse1 and Tse3 can be used, for example, in negative selection cloning in both prokaryotes and eukaryotes.
As used herein, a “gene” is any nucleic acid capable of expressing the recited protein, and thus includes genomic DNA, mRNA, cDNA, etc.
In one preferred embodiment, the first gene comprises or consists of a nucleotide sequence that encode a P. aeruginosa Tse1 or Tse3 amino acid sequence according to SEQ ID NO:10 or SEQ ID NO:12. In another preferred embodiment, the first gene comprises or consists of a nucleotide sequence according to SEQ ID NO:9 or SEQ ID NO:11.
As used herein, “Tse1” and “Tse3” includes functional equivalents (truncations, mutants, etc.) thereof, wherein such equivalents maintain cytotoxic activity as described herein. Methods for identifying such functional equivalents are disclosed herein.
In a further preferred embodiment of any embodiment disclosed above, the first gene encodes a Tse 1 or Tse3-transduction domain conjugate. As disclosed below, the Tse proteins are toxic to cells (prokaryotic and eukaryotic) when expressed intracellularly. Transduction domains are discussed above and examples provided, all of which can be used in this aspect of the invention. In another embodiment that can be combined with any of the above embodiments, the first gene further encodes a cell targeting molecule. Cell targeting molecules are discussed above and examples provided, all of which can be used in this aspect of the invention.
In another embodiment, the first gene encodes a Tse1 or Tse3 fusion protein comprising a secretory signal sequence, permitting secretion of the fusion protein to the periplasmic space. Any suitable secretory signal sequence can be used, as are known in the art. The coding region for the secretory peptide may be in any suitable relationship relative to the Tse1 or Tse3 coding sequence, such as positioned to encode the amino terminus of the fusion protein. The coding region can also be designed to permit cleavage of the secretory signal sequence.
The regulatory sequence is “heterologous”, meaning that it is not a naturally occurring Tse1 of Tse3 regulatory region. As used herein, “regulatory sequence” and “promoter” are as defined above.
In one embodiment, the Tse1 or Tse3 gene is operatively linked to a promoter element sufficient to render promoter-dependent controllable gene expression, for example, inducible or repressible by external signals or agents (adding/removing compounds from the growth media for the recombinant cells), or by altering culture conditions (temperature, pH, etc.). Exemplary controllable promoters are those that are alcohol-regulated, tetracycline-regulated, steroid-regulated, metal-regulated, pathogen-regulated, light-regulated, or temperature-regulated, For use in bacterial systems, many controllable promoters are known (Old and Primrose, 1994). Common examples include Plac (IPTG), Ptac (IPTG), lambdaPR (loss of CI repressor), lambdaPL (loss of CI repressor), Ptrc (IPTG), Ptrp (IAA). The controlling agent is shown in brackets after each promoter. Examples of controllable plant promoters include the root-specific ANR1 promoter (Zhang and Forde (1998) Science 279:407) and the photosynthetic organ-specific RBCS promoter (Khoudi et al. (1997) Gene 197:343). Further exemplary controllable promoters include the Tet-system (Gossen and Bujard, PNAS USA 89: 5547-5551, 1992), the ecdysone system (No et al., PNAS USA 93: 3346-3351, 1996), the progesterone-system (Wang et al., Nat. Biotech 15: 239-243, 1997), and the rapamycin-system (Ye et al., Science 283:88-91, 1999), arabinose-inducible promoters, and rhamnose-inducible promoters.
Any suitable vector can be used, such as a circular or linear vector, including but not limited to circular or linearized plasmid or viral vectors. Expression vectors and methods for their engineering and isolation are well known in the art (see, e.g., Maniatis et al., supra), or they can be obtained through a commercial vendor, e.g., Invitrogen (Carlsbad, Calif.), Promega (Madison, Wis.), and Statagene (La Jolla, Calif.) and modified as needed. Examples of commercially available expression vectors include pcDNA3 (Invitrogen), Gateway cloning technology (Life Technologies), and pCMV-Script (Stratagene). Vector components, regulatory nucleic acids, etc. are typically available from a commercial source or can be isolated from a natural source (e.g., animal tissue or microorganism) or prepared using a synthetic means such as PCR. The arrangement of the components can be any arrangement practically desired by one of ordinary skill in the art. Vectors used in the present invention can be derived from viral genomes that yield virions or virus-like particles, which may or may not replicate independently as extrachromosomal elements. Virion particles can be introduced into the host cells by infection. The viral vector may become integrated into the cellular genome. Examples of viral vectors for transformation of mammalian cells are SV40 vectors, and vectors based on papillomavirus, adenovirus, Epstein-Barr virus, vaccinia virus, and retroviruses, such as Rous sarcoma virus, or a mouse leukemia virus, such as Moloney murine leukemia virus. For mammalian cells, electroporation or viral-mediated introduction can be used.
In one embodiment, the vector comprises one or more unique restriction enzyme recognition sites, wherein cloning of a nucleic acid insert into the one or more unique restriction enzyme recognition sites disrupts expression of Tse1 or Tse3. The vectors of this embodiment can be used as cloning vehicles, since cloning of an insert into the one or more restriction sites in the vector interrupts Tse2 expression and provide an easily selectable marker—cells with vectors containing no insert have their growth inhibited by Tse1 or Tse3 expression, and those with inserts do not. In one preferred embodiment, one or more unique restriction sites are engineered into the coding region for Tse1 or Tse3 using techniques well know to those of skill in the art, such that cloning an insert into the restriction site disrupts the coding region for Tse1 or Tse3. In this embodiment, the restriction sites can be engineered into the coding region to result in silent nucleotide changes, or may result in one or more changes in the amino acid sequence of Tse1 or Tse3, so long as the encoded Tse1 or Tse3 protein retains cytotoxic activity. Alternatively, the one or more unique restriction sites may be located in regulatory regions such that cloning of an insert would disrupt expression of Tse1 or Tse3 from the vector. Design and synthesis of nucleic acid sequences and preparation of vectors comprising such sequences is well within the level of skill in the art.
The invention relates to a novel cloning vector which includes at least one promoter nucleotide sequence and at least one nucleotide sequence encoding a fusion protein (Tse1 and/or Tse3) which is active as a poison, the nucleotide sequence being obtained by fusing a gene coding nucleotide sequence which includes multiple unique cloning sites (MCS) and a nucleotide sequence which encodes Tse1 and/or Tse3. An analogous system utilizing the prokaryotic death gene ccdB has been described in U.S. Pat. No. 7,176,029, and is incorporated by reference herein in its entirety. Exemplary fusion protein comprise, but are not limited to, lacZα, GFP, RFP, His, TA fusion proteins with Tse1 and/or Tse3.
In one non-limiting embodiment, the cloning vector contains the Tse1 and/or Tse3 gene fused to the C-terminus or N-terminus of LacZα. The expression of the Tse1 and/or Tse3-LacZ fusion protein is controlled by an inducible promoter, such as the lac promoter, such that expression of the Tse1 and/or Tse3-LacZ fusion protein will result in the death of a cell. In certain embodiments, a MCS is contained within the LacZ gene, such that insertion of a DNA fragment disrupts the expression of the lacZα-Tse1 and/or Tse3 gene fusion, permitting growth of only positive recombinants. Cells that contain nonrecombinant vector are killed.
Plasmids according to this embodiment allow doubly digested restriction fragments to be cloned in both orientations with respect to the lac promoter. Insertion of a restriction fragment into one of the unique cloning sites interrupts the genetic information of the gene fusion, leading to the synthesis of a gene fusion product which is not functional. Insertional inactivation of the gene fusion ought always to take place when a termination codon is introduced or when a change is made in the reading frame.
The cells which harbor a recombinant vector (disrupted Tse1 and/or Tse3) will be viable while cells which harbor an intact vector (intact Tse1 and/or Tse3) will not be viable. This negative selection, by simple culture on a solid medium, makes it possible to eliminate cells which harbor a non-recombinant vector (non-viable clones) and to select recombinant clones (viable clones).
In another embodiment, the recombinant vector comprises one or more recombination sites flanking the Tse1 and/or Tse3 gene. In a preferred embodiment, the recombinant vector comprises at least a first and a second recombination site flanking a first gene coding for Tse1 and/or Tse3 operatively linked to a regulatory sequence, wherein said first and second recombination sites do not recombine with each other. As used herein, a “recombination site” is a discrete section or segment of DNA that is recognized and bound by a site-specific recombination protein during the initial stages of integration or recombination. For example, the recombination site for Cre recombinase is loxP, a 34 base pair sequence comprised of two 13 base pair inverted repeats (serving as the recombinase binding sites) flanking an 8 base pair core sequence. See Sauer, B., Curr. Opin. Biotech. 5:521-527 (1994). Other examples of recognition sequences include the attB, attP, attL, and attR sequences which are recognized by the recombination protein lambda. attB is an approximately 25 base pair sequence containing two 9 base pair core-type Int binding sites and a 7 base pair overlap region, while attP is an approximately 240 base pair sequence containing core-type Int binding sites and arm-type Int binding sites as well as sites for auxiliary proteins integration host factor (IHF), FIS and excisionase (Xis). See Landy, Curr. Opin. Biotech. 3:699 707 (1993). Further examples of recognition sequences include loxP site mutants, variants or derivatives such as loxP511 (see U.S. Pat. No. 5,851,808); dif sites; dif site mutants, variants or derivatives; psi sites; psi site mutants, variants or derivatives; cer sites; and cer site mutants, variants or derivatives. See also, for example, US20100267128 and WO 01/11058, incorporated by reference herein in their entirety. Other systems providing recombination sites and recombination proteins for use in the invention include the FLP/FRT system from Saccharomyces cerevisiae, the resolvase family (e.g., RuvC, yi, TndX, TnpX, Tn3 resolvase, Hin, Hjc, Gin, SpCCE1, ParA, and Cin), and IS231 and other Bacillus thuringiensis transposable elements. Other suitable recombination systems for use in the present invention include the XerC and XerD recombinases and the psi, dif and cer recombination sites in Escherchia coli. Other suitable recombination sites may be found in U.S. Pat. No. 5,851,808, which is specifically incorporated herein by reference.
This embodiment can be used for recombinational cloning, for example using the system described in published U.S. Pat. Application No. US20100267128, and in U.S. application Ser. No. 09/177,387, filed Oct. 23, 1998; U.S. application Ser. No. 09/517,466, filed Mar. 2, 2000; and U.S. Pat. Nos. 5,888,732 and 6,143,557, all of which are specifically incorporated herein by reference. In brief, the disclosed system utilizes vectors that contain at least two different site-specific recombination sites based on the bacteriophage lambda system (e.g., att1 and att2) that are mutated from the wild-type (att0) sites. Each mutated site has a unique specificity for its cognate partner att site (i.e., its binding partner recombination site) of the same type (for example attB1 with attP 1, or attL1 with attR1) and will not cross-react with recombination sites of the other mutant type or with the wild-type att0 site. Different site specificities allow directional cloning or linkage of desired molecules thus providing desired orientation of the cloned molecules. Nucleic acid fragments flanked by recombination sites are cloned and subcloned by replacing a selectable marker (Tse1 and/or Tse3) flanked by att sites on the recipient plasmid molecule. Desired clones are then selected by transformation of a Tse1 and/or Tse3 sensitive host strain and positive selection for a marker on the recipient molecule. Tse1 and/or Tse3 is toxic to both prokaryotic and eukaryotic cells, and thus Tse1 and/or Tse3 sensitive host strains include both prokaryotic and eukaryotic cells.
In one embodiment, the vector contains a Tse1 and/or Tse3 gene flanked by one or more restriction enzyme sites or recombination sites. Recombination sites include, but are not limited to, attB, attP, attL, and attR. This vector is designed such that the DNA fragment of interest (such as, for example, a PCR product) will replace the Tse1 and/or Tse3 located between the two flanking sites. If the DNA fragment of interest is present in the vector, the cells containing the vector survive, as the Tse1 and/or Tse3 gene will no longer be present on the desired recombinant vector. If the gene of interest is not present, the Tse1 and/or Tse3 gene will prevent survival of the cell carrying the undesired vector. Thus, only cells containing positive clones with the DNA fragment of interest will be viable, and easily selected for.
In one embodiment, the vector comprises at least one inactive fragment of the Tse1 and/or Tse3 gene, wherein a functional Tse1 and/or Tse3 gene is rescued when the inactive fragment is recombined across at least one recombination site with a second DNA segment comprising another inactive fragment of the Tse1 and/or Tse3 gene.
In addition to components of the vector which may be required for expression of Tse1 or Tse3, vectors may also include any other suitable control elements, including but not limited to origin of replication, primer sites, e.g., for PCR, transcriptional and/or translational initiation and/or regulation sites, recombinational signals, replicons, other selection markers, antibiotic resistance genes, etc. In one embodiment, the replication sequence renders the vector capable of episomal and chromosomal replication, such that the vector is capable of self-replication as an extrachromosomal unit and of integration into the chromosome, either due to the presence of a translocatable sequence, such as an insertion sequence or transposon, due to substantial homology with a sequence present in the chromosome or due to non-homologous recombinational events. The replication sequence or replicon will be one recognized by the transformed host and is derived from any convenient source, such as from a plasmid, virus, the host cell, e.g., an autonomous replicating segment, by itself, or in conjunction with a centromere, or the like. The particular replication sequence is not critical to the subject invention and various sequences may be employed. Conveniently, a replication sequence of a virus can be employed.
In a twelfth aspect, the present invention provides recombinant host cells comprising the recombinant vector of any embodiment or combination of embodiments of the eleventh aspect of the invention. A “host,” as the term is used herein, can be any prokaryotic or eukaryotic organism that can be genetically engineered to express heterologous Tse1 or Tse3 including but not limited to bacterial (such as E. coli), algal, fungal (such as yeast), insect, invertebrate, plant, and mammalian cell types. For examples of such hosts, see Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1982). The host cells of this aspect of the invention can be used, for example, in the methods of the invention discussed below.
In a thirteenth aspect, the present invention provides methods for selectable cloning, comprising culturing the recombinant host cell of any embodiment of the twelfth aspect of the invention under conditions suitable for expression of Tse1 or Tse3 from the recombinant vector if no insert is present, and selecting those cells that grow as comprising recombinant vectors with the insert cloned into the expression vector. In one embodiment, the vector comprises one or more unique restriction enzyme recognition sites, and wherein cloning of a nucleic acid insert into the one or more unique restriction enzyme recognition sites disrupts expression of the first gene, and cloning of an insert into the one or more restriction sites in the vector interrupts Tse1 or Tse3 expression and provide an easily selectable marker—cells comprising vectors containing no insert have their growth inhibited by Tse1 or Tse3 expression, and those with inserts do not. In another embodiment, the recombinant vector comprises at least a first and a second recombination site flanking a first gene coding for Tse1 or Tse3 operatively linked to a regulatory sequence, wherein said first and second recombination sites do not recombine with each other. In this embodiment, nucleic acid fragments to be cloned are flanked by recombination sites and cloned/subcloned by replacing the Tse1 or Tse3 selectable marker flanked by recombination sites on the recombinant vector. Desired clones are then selected by transformation of a Tse1 or Tse3 sensitive host strain and any positive selection for a marker on the recipient molecule. Tse1 or Tse3 is toxic to both prokaryotic and eukaryotic cells, and thus Tse1 or Tse3 sensitive host strains include both prokaryotic and eukaryotic cells. Since Tse1 or Tse3 is toxic in both prokaryotic and eukaryotic cells, such selectable cloning can be carried out in any prokaryotic or eukaryotic host cell, including but not limited to bacterial (such as E. coli), algal, fungal (such as yeast), insect, invertebrate, plant, and mammalian cell types. Conditions for cell culture suitable for Tse1 or Tse3 expression can be determined by those of skill in the art based on a variety of factors, including the specific host cell, regulatory sequence(s), and vector design in light of the teachings herein.
In a fourteenth aspect, the present invention provides methods for producing a cloning vector that lacks an insert, comprising culturing the recombinant host cell of any embodiment of the twelfth aspect of the invention under conditions suitable for vector replication and expression of Tse1 or Tse3, wherein the recombinant host cells further express a Tse1 or Tse3 antidote, and isolating vector from the host cells. These methods permit large scale production of the vectors of any embodiment of the present invention. The antidote can be any expression product capable of interfering with the cytotoxic activity of Tse1 or Tse3, including but not limited to Tse1 or Tse3 antisense constructs, Tse1 or Tse3-binding aptamers, and Tse1 or Tse3-binding polypeptides.
The present invention may be better understood with reference to the accompanying examples that are intended for purposes of illustration only and should not be construed to limit the scope of the invention, as defined by the claims appended hereto.
The functional spectrum of a secretion system is defined by its substrates. Here we analyzed the secretomes of Pseudomonas aeruginosa mutants altered in regulation of the Hcp Secretion Island-1-encoded type VI secretion system (H1-T6SS). We identified three substrates of this system, proteins Tse1-3 (type six exported 1-3), which are co-regulated with the secretory apparatus and secreted under tight posttranslational control. The Tse2 protein was found to be the toxin component of a toxin-immunity system, and to arrest the growth of prokaryotic and eukaryotic cells when expressed intracellularly. In contrast, secreted Tse2 had no effect on eukaryotic cells; however, it provided a major growth advantage for P. aeruginosa strains, relative to those lacking immunity, in a manner dependent on cell contact and the H1-T6SS. This demonstration that the T6SS targets a toxin to bacteria helps reconcile the structural and evolutionary relationship between the T6SS and the bacteriophage tail and spike.
Secreted proteins allow bacteria to intimately interface with their surroundings and other bacteria. The importance and diversity of secreted proteins is reflected in the multitude of pathways bacteria have evolved to enable their export (Abdallah et al., 2007; Filloux, 2009). Large multi-component secretion systems, including types III and IV secretion, have been the focus of a great deal of study because in many organisms they are specialized for effector export and they have the remarkable ability to directly translocate proteins from bacterial to host cell cytoplasm via a needle-like apparatus (Cambronne and Roy, 2006). The recently described type VI secretion system (T6SS) is another specialized system, however its physiological role and general mechanism remain poorly understood (Bingle et al., 2008).
Studies of T6SSs indicate that a functional apparatus requires the products of approximately 15 conserved and closely linked genes, and is strongly correlated to the export of a hexameric ring-shaped protein belonging to the hemolysin co-regulated protein (Hcp) family (Filloux, 2009; Mougous et al., 2006). Hcp proteins are required for assembly of the secretion apparatus and they interact with valine-glycine repeat (Vgr) family proteins, which are also exported by the T6SS. The function of the Hcp/Vgr complex remains unclear, however it is believed that the proteins are extracellular structural components of the secretion apparatus. Recent X-ray crystallographic insights into Hcp and Vgr-family proteins show that they are similar to bacteriophage tube and tail spike proteins, respectively (Leiman et al., 2009; Pell et al., 2009). These findings prompted speculation that the T6SS is evolutionarily, structurally, and mechanistically related to bacteriophage. According to this model, the T6SS assembles as an inverted phage tail on the surface of the bacterium, with the Hcp/Vgr complex forming the distal end of the cell-puncturing device. Another notable conserved T6S gene product is ClpV, a AAA+-family ATPase that has been postulated to provide the energy necessary to drive the secretory apparatus (Mougous et al., 2006). The roles of the remaining conserved T6S proteins remain largely unknown.
Nonconserved genes encoding predicted accessory elements are also linked to most T6SSs (Bingle et al., 2008). In the HSI-I-encoded T6SS of Pseudomonas aeruginosa (H1-T6SS) (
The T6SS has been linked to a myriad of processes, including biofilm formation (Aschtgen et al., 2008; Enos-Berlage et al., 2005), conjugation (Das et al., 2002), quorum sensing regulation (Weber et al., 2009), and both promoting and limiting virulence (Filloux, 2009). The P. aeruginosa H1-T6SS has been implicated in the fitness of the bacterium in a chronic infection; mutants in conserved genes in this secretion system failed to efficiently replicate in a rat lung chronic infection model and the system was shown to be active in cystic fibrosis (CF) patient infections (Mougous et al., 2006; Potvin et al., 2003). The H1-T6SS is also co-regulated with other chronic infection virulence factors such as the psl and pel loci, which are involved in biofilm formation (Goodman et al., 2004; Ryder et al., 2007).
How the apparently conserved T6SS architecture can participate in such a wide range of activities is not clear. At least one mechanism by which the secretion system can exert its effects on a host cell has been garnered from studies of Vibrio cholerae. A T6S-associated VgrG-family protein of this organism contains a domain with actin-crosslinking activity that is translocated into host cell cytoplasm in a process requiring endocytosis and cell-cell contact (Ma et al., 2009; Pukatzki et al., 2007; Satchell, 2009). The subset of VgrG-family proteins that contain non-structural domains with conceivable roles in pathogenesis have been termed “evolved” VgrG proteins (Pukatzki et al., 2007). This configuration, wherein an effector domain is presumably translocated into host cell cytoplasm by virtue of its fusion to the T6S cell puncturing apparatus, is intriguing, but it is likely not general; a multitude of organisms containing T6SSs do not encode “evolved” VgrG proteins (Boyer et al., 2009; Pukatzki et al., 2009).
Key to understanding the function of the T6SS—as with any secretion system—is to identify and characterize the protein substrates that it exports. EvpP from Edwardsiella tarda and RbsB from Rhizobium leguminosarum are proposed substrates of the system; however, inconsistent with anticipated properties of T6S substrates, RbsB contains an N-terminal Sec secretion signal, and EvpP stably associates with a component of the secretion apparatus (Bladergroen et al., 2003; Pukatzki et al., 2009; Zheng and Leung, 2007).
In this study, we identified three proteins, termed Tse1-3 (type VI secretion exported 1-3), that are substrates of the H1-T6SS of P. aeruginosa. We showed that one of these, Tse2, is the toxin component of a toxin-immunity system, and that it is able to arrest the growth of a variety of prokaryotic and eukaryotic organisms. Despite the promiscuity of toxin expressed intracellularly, we found that H1-T655-exported Tse2 was specifically targeted to bacteria. In growth competition experiments, immunity to Tse2 provided a marked growth advantage in a manner dependent on intimate cell-cell contact and a functional H1-T6SS. The ability of the secretion system to efficiently target Tse2 to a bacterium, and not to a eukaryotic cell, suggests that T6S may play a role in the delivery of toxin and effector molecules between bacteria.
Under laboratory culturing conditions, activation of the H1-T6SS is strongly repressed at the posttranslational level by the phosphatase PppA (
To probe whether the on-state and off-state mutations could modulate the activity of the H1-T6SS, we assayed their effect on Hcp1 secretion in P. aeruginosa PAO1 hcp1-V (where present, -V denotes a fusion of the indicated gene to a sequence encoding the vesicular stomatitis virus G epitope). As expected, the deletion of pppA promoted Hcp1 secretion and Fha1 phosphorylation relative to the parental strain (
Next, we used MS and spectral counting to compare proteins present in the secretomes of the on- and off-state P. aeruginosa strains (Liu et al., 2004). Average spectral count (SC) values were used to identify whether each protein was differentially secreted between states. The results of our MS analyses are summarized in Table S1. Importantly, the total number of spectral counts was comparable between the on- and off-states in both replicates. A total of 371 proteins that met our filtering criteria were identified between replicate experiments (Tables S2). We divided the proteins into three groups: Category 1 (C1; Tables S3 and S4)—present in both the on- and off-states, Category 2 (C2; Table S5)—present only in the on-state, and Category 3 (C3; Table S6)—present only in the off-state. Overlap between the replicates was greatest among C1 proteins. A total of 314 C1 proteins were identified, of which 249 were shared between the replicates. A significant fraction of the C1 differences can be ascribed to the fact that 13% more proteins were identified in this category in Replicate 1 (R1) than in Replicate 2 (R2).
To assess the accuracy of the quantitative component of our datasets, we measured the distribution of SC ratios (on-state/off-state) within C1 proteins (
As expected, Hcp1 was over-represented in the on-state samples. Indeed, Hcp1 was the most differentially secreted protein in both datasets (SC ratio: [R1], 13; [R2], 17]) (
Next we analyzed C2 proteins—those observed only in the on-state. Similar numbers of these proteins were identified in R1 (19) and R2 (20), and five of these were found in both replicates (Table 1). The reproducibility of C2 versus C1 proteins is attributable to the difference in their average SCs; the average SC of C2 proteins was 2.6, versus 12 in C1. The C2 proteins identified in both R1 and R2 accounted for five of the six most abundant in C2-R1, and five of the ten most abundant in C2-R2. Each of these proteins lacked a secretion signal for known export pathways. The identity of these proteins and the biochemical validation of their secretion is the subject of subsequent sections.
The number and abundance of C3 proteins in both R1 and R2 was slightly lower than the corresponding C2 values. Nonetheless, we did identify three C3 proteins in common between R1 and R2 (Table 1). The occurrence of these proteins in the off-state is likely to reflect changes in gene regulation caused by modulation of the activity of the H1-T6SS that manifest in the secretome. Sequence analysis indicated that each of these proteins contains a predicted signal peptide (Emanuelsson et al., 2007).
Two VgrG-family proteins, the products of open reading frames PA0091 and PA2685, were the most abundant C2 proteins in R1 and R2 (Table 1). Interestingly, earlier microarray work has shown that PA0091 and PA2685 are coordinately regulated with HSI-I by the RetS hybrid two-component sensor/response regulator protein, however the participation of these proteins in the H1-T6SS was not investigated (
To confirm the MS results, we compared the localization of VgrG1 and VgrG4 in wild-type bacteria to strains containing the on-state (ΔpppA) and off-state (ΔclpV1) mutations. Consistent with our MS findings, Western blot analyses of cell and supernatant fractions in vgrG1-V and vgrG4-V backgrounds indicated that secretion of the proteins is strongly repressed by pppA and requires clpV1 (
The remaining C2 proteins identified in both R1 and R2 are proteins encoded by ORFs PA1844, PA2702, and PA3484. Interestingly, an earlier study identified the product of PA1844 as an immunogenic protein expressed by a P. aeruginosa clinical isolate (Wehmhoner et al., 2003). Bioinformatic analyses of the three proteins indicated that they do not share detectable sequence homology to each other or to proteins outside of P. aeruginosa. Each protein is encoded by an ORF that resides in a predicted two-gene operon with a second hypothetical ORF. Intriguingly, we noted that the three unlinked operons—like HSI-I (which includes vgrG1) and vgrG4—are negatively regulated by RetS (
Based on our secretome analyses, we hypothesized that the proteins encoded by PA1844, PA2702, and PA3484, henceforth referred to Tse1-3, respectively, are substrates of the H1-T6SS. To test this, we analyzed the localization of the proteins when ectopically expressed in a diagnostic panel of P. aeruginosa strains. The secretion profile of each protein was similar in these strains; relative to the wild-type, ΔpppA displayed dramatically increased levels of secretion, and secretion levels were at or below wild-type levels in ΔpppA strains containing additional deletions in either hcp1 or clpV1 (
To further distinguish the Tse proteins as H1-T6SS substrates rather than structural components, we determined their influence on core functions of the T6 secretion apparatus. Fundamental to each studied T6SS is the ability to secrete an Hcp-related protein. In a systematic analysis, Hcp secretion was shown to require all predicted core T6SS components, including VgrG-family proteins (Pukatzki et al., 2007; Zheng and Leung, 2007). We generated a strain containing a deletion of all tse genes in the ΔpppA hcp1-V background and compared Hcp1 secretion in this strain to strains lacking both vgrG1 and vgrG4 or clpV1 in the same background. Western blot analysis revealed that Hcp1 secretion was abolished in both the ΔclpV1 and ΔvgrG1 ΔvgrG4 strains, however it was unaffected by tse deletion (
A multiprotein complex containing ClpV1 is essential for a functional T6S apparatus (Hsu et al., 2009). As a second indicator of H1-T6SS function, we used fluorescence microscopy to examine the formation of this complex in strains containing a chromosomal fusion of clpV1 to a sequence encoding the green fluorescent protein (clpV1-GFP) (Mougous et al., 2006). In line with the Hcp1 secretion result, the punctate appearance of ClpV1-GFP localization, which is indicative of proper apparatus assembly, was not dependent on the tse genes (
Earlier microarray experiments suggested that the tse genes are tightly repressed by RetS, a component of the Gac/Rsm signaling pathway (Lapouge et al., 2008). In this pathway, the activity of RetS and two other sensor kinase enzymes, LadS and GacS, converge to reciprocally regulate an overlapping group of acute and chronic virulence pathways in P. aeruginosa through the small RNA-binding protein RsmA (Brencic and Lory, 2009; Goodman et al., 2004; Ventre et al., 2006). To directly investigate the effect of the Gac/Rsm pathway on tse expression, we monitored the abundance of Tse proteins in the cell-associated and secreted fractions of strains containing the rets deletion. Our data showed that activation of the Gac/Rsm pathway dramatically elevates cellular Tse levels and triggers their export via the H1-T6SS (
Tsi2 is an Essential Protein that Protects P. aeruginosa from Tse2
The lack of transposon insertions within the tse2/tsi2 locus in a published transposon insertion library of P. aeruginosa PAO1 suggested that these ORFs may be essential for viability of the organism (Jacobs et al., 2003). To test this possibility, we attempted to generate deletions of tse2 and tsi2. While a Δtse2 strain was readily constructed, tsi2 was refractory to several methods of deletion. Based on genetic context and co-regulation (
Our findings implied that Tsi2 protects cells from Tse2. To probe this possibility further, we introduced tse2 to the Δtse2 Δtsi2 background. Induction of tse2 expression completely abrogated growth of Δtse2 Δtsi2, however it had only a mild effect on wild-type cells. These data demonstrate that tse2 encodes a toxic protein capable of inhibiting the growth of P. aeruginosa, and that tsi2 encodes a cognate immunity protein. We named Tsi2 based on this property (type VI secretion immunity protein 2).
Tsi2 could block the activity of Tse2 through a mechanism involving direct interaction of the proteins, or by an indirect mechanism wherein the proteins function antagonistically on a common pathway. To determine if Tse2 and Tsi2 physically interact, we conducted co-immunoprecipitation studies in P. aeruginosa. Tse2 was specifically identified in precipitate of Tsi2-V, indicative of a stable Tse2-Tsi2 complex (
P. aeruginosa is widely dispersed in terrestrial and aquatic environments, and it is also an opportunistic pathogen with a diverse host range. As such, Tse2 exported from P. aeruginosa has the potential to interact with a range of organisms, including prokaryotes and eukaryotes. To investigate the organisms that Tse2 might target, we expressed tse2 in the cytoplasm of representative species from each domain. Two eukaryotic cells were chosen for our investigation, Saccharomyces cerevisiae and the HeLa human epithelial-derived cell line. Yeast were included primarily for diversity, however these organisms also interact with P. aeruginosa in assorted environments and could therefore represent a target of the toxin (Wargo and Hogan, 2006). S. cerevisiae cells were transformed with a galactose-inducible expression plasmid for each tse gene, or with an empty control plasmid (Mumberg et al., 1995). Relative to the other tse genes and the control, tse2 expression caused a dramatic decrease in observable colony forming units following 48 hrs of growth under inducing conditions (
The effects of Tse2 on a mammalian cell were probed using a reporter co-transfection assay in HeLa cells. Expression plasmids containing the tse genes were generated and mixed with a GFP reporter plasmid. Co-transfection of the reporter plasmid with tse1 and tse3 had no impact on GFP expression relative to the control; however, inclusion of the tse2 plasmid reduced GFP expression to background levels (
Next we asked whether Tse2 has activity in prokaryotes other than P. aeruginosa. We tested two organisms, Escherichia coli and Burkholderia thailandensis. Both organisms were transformed with plasmids engineered for inducible expression of either tse2, or as a control, both tse2 and tsi2. In each case, tse2 expression strongly inhibited growth and co-expression with tsi2 reversed this effect (
P. aeruginosa Can Target Bacterial, but Not Eukaryotic Cells, with Tse2
Since tse2 expression experiments indicated that the toxin could act on eukaryotes (
The influence of intracellular tse2 expression on the growth of bacteria prompted us to next investigate whether its target could be another prokaryotic cell. To test this, we conducted a series of in vitro growth competition experiments with P. aeruginosa strains in the ΔretS background engineered with regard to their ability to produce, secrete, or resist Tse2. Competitions between these strains were conducted in liquid medium or following filtration onto a porous solid support. Neither production nor secretion of Tse2, nor immunity to the toxin, impacted the growth rates of competing strains in liquid medium (
In order to examine the extent to which Tse2 could facilitate a growth advantage, we conducted long-term competitions between strains with and without Tse2 immunity. The experiments were initiated with a donor-to-recipient cell ratio of approximately 10:1, raising the probability that each recipient cell will contact a donor cell. After 48 hours, the Tse2 donor strain displayed a remarkable 104-fold growth advantage relative to a recipient strain lacking immunity (
The T6SS has been implicated in numerous, apparently disparate processes. With few exceptions, the mode-of-action of the secretion system in these processes is not known. Since the T6SS architecture appears highly conserved, we based our study on the supposition that the diverse activities of T6SSs, including T6SSs within a single organism, must be attributable to a diverse array of substrate proteins exported in a specific manner by each system. Our findings support this model; we identified three T6S substrates that lack orthologs outside of P. aeruginosa, and that specifically require the H1-T6SS for their export (
Bacterial genomes encode a large and diverse array of toxin-immunity protein (TI) systems (Gerdes et al., 2005). These can be important for plasmid maintenance, stress response, programmed cell death, cell-fate commitment, and defense against other bacteria. Tse2 differs from other TI toxins in that it is exported through a large, specialized secretion apparatus, while many TI system toxins are either not actively secreted, or they utilize the sec pathway (Riley and Wertz, 2002). This distinction implies that secretion through the T6S apparatus is required to target Tse2 to a relevant environment, cell, or subcellular compartment. Indeed, we have shown that targeting of Tse2 by the T6S apparatus is essential for its activity (
We found that Tse2 is active against assorted bacteria and eukaryotic cells when expressed intracellularly (
It is also evident that in certain instances the T6SS has evolved to engage eukaryotic cells. In at least two reports, the T6S apparatus has been demonstrated to deliver a protein to a eukaryotic cell (Ma et al., 2009; Suarez et al., 2009). Moreover, the T6SSs of several pathogenic bacteria are major virulence factors (Bingle et al., 2008). Taken together with our findings, we posit that there are two broad groups of T6SSs, those that target bacteria and those that target eukaryotes. It is not possible at this time to rule out that a given T6SS may have dual specificity. However, our inability to detect the effects of Tse2 in an infection of a eukaryotic cell, and the fact that a Tse2 hyper-secreting strain is attenuated in animal models of acute infection (Laskowski et al., 2004; Zolfaghar et al., 2006), suggests that the T6S apparatus can be highly discriminatory. In this regard, it is instructive to consider other secretion systems that have evolved from inter-bacterial interaction pathways. The type IVA and type IVB secretion systems are postulated to have evolved from a bacterial conjugation system ((Burns, 2003; Christie et al., 2005; Lawley et al., 2003). These systems have become efficient at eukaryotic cell intoxication, however measurements indicate that substrate translocation into bacteria occurs at a frequency of only ˜1×10−6/donor cell (Luo and Isberg, 2004). In contrast, Tse2 targeting to bacteria by the H1-T6SS appears many orders of magnitude more efficient, as the donor strain in our assays is able to effectively suppress the net growth of an equal amount of recipient cells. The host adapted type IV secretion systems and the H1-T6SS represent two apparent extremes in the cellular targeting specificity of Gram-negative specialized secretion systems. Furthermore, they show that a high degree of discrimination can exist between pathways targeting eukaryotes and prokaryotes.
The physiologically relevant target bacteria of Tse2 and the H1-T6SS remains an open question. We have initiated studies to address the role of these factors in interspecies interactions, however we have not yet identified an effect. This may be because diffusible anti-bacterial molecules released by P. aeruginosa dominate the outcome of growth competitions performed under the conditions used in
The cell-cell contact requirement of H1-T6SS-dependent delivery of Tse2 suggest that the system could play an important role in scenarios involving relatively immobile cells, such as cells encased in a biofilm. The polyclonal and polymicrobial lung infections of patients with CF, wherein the bacteria are thought to reside within biofilm-like structures, is one setting where Tse2 could provide a fitness advantage to P. aeruginosa (Sibley et al., 2006; Singh et al., 2000). Intriguingly, P. aeruginosa is particularly adept at adapting to and competing in this environment, and studies have shown that it can even displace preexisting bacteria (D'Argenio et al., 2007; Deretic et al., 1995; Hoffman et al., 2006; Nguyen and Singh, 2006) (Foundation, 2007). If Tse2 does play a key role in the fitness of P. aeruginosa in a CF infection, this could explain the elevated expression and activation of the H1-T6SS observed in isolates from CF patients (Mougous et al., 2006; Mougous et al., 2007; Starkey et al., 2009; Yahr, 2006).
The P. aeruginosa strains used in this study were derived from the sequenced strain PAO1 (Stover et al., 2000). P. aeruginosa were grown on Luria-Bertani (LB) medium at 37° C. supplemented with 30 μg ml−1 gentamicin, 300 μg ml−1 carbenicillin, 25 μg ml−1 irgasan, 5% w/v sucrose, 0.5 mM IPTG and 40 μg ml−1 X-gal (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside) as required. Burkholderia thailandensis E264 and Escherichia coli BL21 were grown on LB medium containing 200 μg ml−1 trimethoprim, 50 μg ml−1 kanamycin, 0.2% w/v glucose, 0.2% w/v rhamnose and 0.5 mM IPTG as required. E. coli SM10 used for conjugation with P. aeruginosa was grown in LB medium containing 15 μg ml−1 gentamicin. Plasmids used for inducible expression include pPSV35, pPSV35CV, and pSW196 for P. aeruginosa (Baynham et al., 2006; Hsu et al., 2009; Rietsch et al., 2005), pET29b (Novagen) for E. coli, pSCrhaB2 (Cardona and Valvano, 2005) for B. thailandensis, and p426-GAL-L and p423-GAL-L for S. cerevisiae (Mumberg et al., 1995). Chromosomal fusions and gene deletions were generated as described previously (Mougous et al., 2006; Rietsch et al., 2005). See Supplemental Experimental Procedures for specific cloning procedures.
Cells were grown to optical density 600 nm (OD600) 1.0 in Vogel-Bonner minimal medium containing 19 mM amino acids as defined in synthetic CF sputum medium (Palmer et al., 2007). The presence of amino acids was required for H1-T6SS activity (data not shown). Proteins were prepared as described previously (Wehmhoner et al., 2003).
Precipitated proteins were suspended in 100 μl of 6 M urea in 50 mM NH4HCO3, reduced and alkylated with dithiotreitol and iodoactamide, respectively, and digested with trypsin (50:1 protein:trypsin ratio). The resultant peptides were desalted with Vydac C18 columns (The Nest Group) following the manufacturer's protocol. Samples were dried to 5 μL, resuspended in 0.1% formic acid/5% acetonitrile and analyzed on an LTQ-Orbitrap mass spectrometer (Thermo Fisher) in triplicate. Data was searched using Sequest (Eng et al., 1994) and validated with Peptide/Protein Prophet (Keller et al., 2002). The relative abundance for identified proteins was calculated using spectral counting (Liu et al., 2004). See Supplemental Experimental Procedures additional MS procedures.
Cell-associated and supernatant samples were prepared as described previously (Hsu et al., 2009). Western blotting was performed as described previously (Mougous et al., 2006), with the exception that detection of the Tse proteins required primary antibody incubation in 5% BSA in Tris-buffered saline containing 0.05% v/v Tween 20 (TBST). The GSK tag was detected using α-GSK (Cell Signaling Technologies).
Cells grown in appropriate additives were harvested at mid-log phase by centrifugation (6,000×g, 3 min) at 4° C. and resuspended in 10 ml of Buffer 1 (200 mM NaCl, 20 mM Tris pH 7.5, 5% glycerol, 2 mM dithiothreitol, 0.1% triton) containing protease inhibitors (Sigma) and lysozyme (0.2 mg ml−1). Cells were disrupted by sonication and the resulting lysate was clarified by centrifugation (25,000×g, 30 min) at 4° C. A sample of the supernatant material was removed (Pre) and the remainder was incubated with 100 μl of α-VSV-G agarose beads (Sigma) for 2 hours at 4° C. for. Beads were washed three times with 15 ml of Buffer 1 and pelleted by centrifugation. Proteins were eluted with SDS-PAGE loading buffer.
Mid-log phase cultures were harvested by centrifugation (6,000×g, 3 min), washed with phosphate-buffered saline (PBS), and resuspended to OD600 5 with PBS containing 0.5 mM TMA-DPH (Molecular Probes). Microscopy was performed as described previously (Hsu et al., 2009). All images shown were manipulated identically.
Saccharomyces cerevisiae BY4742 (MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0) was transformed with p426-GAL-L containing tse1, tse2, tse3, or the empty vector, and grown o/n in SC−Ura+2% glucose (Mumberg et al., 1995). Cultures were resuspended to OD600 1.0 with water and serially diluted fivefold onto SC−Ura+2% glucose agar or SC−Ura+2% galactose+2% raffinose agar. Plates were incubated at 30° C. for 2 days before being photographed. The tsi2 gene was cloned into p423-GAL-L and transformed into S. cerevisiae BY4742 harboring the p426-GAL-L plasmid. Cultures were grown o/n in SC−Ura-His+2% glucose.
Overnight cultures were mixed at the appropriate donor-to-recipient ratio to a total density of approximately 1.0×108 CFU/ml in 5 ml LB medium. In each experiment, either the donor or recipient strain contained lacZ inserted at the neutral phage attachment site (Vance et al., 2005). This gene had no effect on competition outcome. Co-cultures were either filtered onto a 47-mm 0.2 μm nitrocellulose membrane (Nalgene) and placed onto LB agar or were inoculated 1:100 into 2 ml LB (containing 0.4% w/v L-arabinose, if required), and were incubated at 37° C. with shaking Filter-grown cells were resuspended in LB medium and plated on LB agar containing X-gal.
HeLa cells were cultured and maintained in Dulbecco's modified eagle medium (DMEM, Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS) and 100 μml−1 penicillin or streptomycin as required. Incubations were performed at 37° C. in the presence of 5% CO2. Infection assays were carried out using cells seeded in 96-well plates at a density of 2.0×104 cells/well. Following o/n incubation, wells were washed in 1× Hank's balanced salt solution and DMEM lacking sodium pyruvate and antibiotics was added. Bacterial inoculum was added to wells at a multiplicity of infection of 50 from cultures of OD600 1.0. Following incubation for 5 hours, the percent cytotoxicity was measured using the CytoTox-One assay (Promega).
HeLa cells were seeded in 24-well flat bottom plates at a density of 2.0×105 cells/well and incubated o/n in DMEM supplemented with 10% FBS. Reporter co-transfection experiments were performed using Lipofectamine according to the manufacturer's protocol. Total amounts of transfected DNA were normalized using equal quantities of the GFP reporter plasmid (empty pEGFP-N1 (Clonetech)), one of the tse expression plasmids (pEGFP-N-1-derived), and either a non-specific plasmid or the tsi2 expression plasmid where indicated. Cell rounding was quantified manually using phase-contrast images from three random fields acquired at 40× magnification. Prior to flow cytometry, HeLa cells were washed two times and resuspended in 1×PBS supplemented with 0.75% FBS. Analysis was performed on a BD FACscan2 cell analyzer and mean GFP intensities were calculated using FlowJo 7.5 software (Tree Star, Inc.).
Tse2 and Tsi2 mutants were generated and tested for cytotoxic activity and preservation of immunity to Tse2 cytotoxicity, respectively.
Truncation mutants listed in Table 1 were tested for (a) toxicity as judged by ectopic expression of allele in P. aeruginosa PAO1 Δtse2 Δtsi2., (b) expression as determined by α-VSV-G Western blot, and (c) secretion determined by presence of indicated protein in concentrated supernatants prepared from PAO1 ΔretS Δtse2 versus PAO1 ΔretS Δtse2 ΔclpV1. The mutants listed in Table 1 are based on the P. aeruginosa PAO1 sequence (SEQ ID NO:2). All truncations were fused at their C-terminus to the VSV-G epitope.
The lack of toxicity observed for those alleles that did not express fully (+/−) could be attributed to expression levels. The data presented in Table 1 show that Tse2 residues 1-6 and 156-158 are not required for toxicity.
A variety of Tse2 point mutants (Table 2) were also generated by Quikchange mutagenesis in the pPSV35-CV vector (see Hsu and Mougous, 2009 for plasmid reference). Toxicity, expression, and secretion were assessed as for the truncation mutants in Table 1.
We next generated a series of Tsi2 mutants and tested for Tse2-immunity properties. Immunity was determined by ectopic expression of the indicated allele in P. aeruginosa Δtse2 Δtsi2. Growth of the strain indicates Tsi2 provides immunity, as Tse2 is co-expressed. Numbering of the Tsl2 sequence is relative to the Tsi2 sequence of SEQ ID NO:4.
The data presented in Table 3 show that mutations at virtually all positions retained tse2 immunity, demonstrating that Tsi2 is resilient and its interactions are robust. Truncation studies (not shown) demonstrated that residues 60-77 of Tsi2 can be removed while retaining its Tse2 immunity activity.
Bacteria that live in the environment have evolved pathways specialized to defend against eukaryotic organisms or other bacteria. In this manuscript, we systematically examined the role of the five type VI secretion systems (T6SSs) of Burkholderia thailandensis (B. thai) in eukaryotic and bacterial cell interactions. Consistent with phylogenetic analyses comparing the distribution of the B. thai T6SSs with well characterized bacterial and eukaryotic cell-targeting T6SSs, we found that T6SS-5 plays a critical role in the virulence of the organism in a murine melioidosis model, while a strain lacking the other four T6SSs remained as virulent as the wild-type. The function of T6SS-5 appeared to be specialized to the host and not related to an in vivo growth defect, as ΔT6SS-5 was fully virulent in mice lacking MyD88. Next we probed the role of the five systems in interbacterial interactions. From a group of 31 diverse bacteria, we identified several organisms that competed less effectively against wild-type B. thai than a strain lacking T6SS-1 function. Inactivation of T6SS-1 renders B. thai greatly more susceptible to cell contact-induced stasis by Pseudomonas putida, Pseudomonas fluorescens and Serratia proteamaculans—leaving it 100- to 1000-fold less fit than the wild-type in competition experiments with these organisms. Flow cell biofilm assays showed that T6S-dependent interbacterial interactions are likely relevant in the environment. B. thai cells lacking T6SS-1 were rapidly displaced in mixed biofilms with P. putida, whereas wild-type cells persisted and overran the competitor. Our data show that T6SSs within a single organism can have distinct functions in eukaryotic versus bacterial cell interactions. These systems are likely to be a decisive factor in the survival of bacterial cells of one species in intimate association with those of another, such as in polymicrobial communities present both in the environment and in many infections.
Many bacteria encounter both eukaryotic cells and other bacterial species as a part of their lifestyles. In order to compete and survive, these bacteria evolved specialized pathways that target these distinct cell types. Type VI secretion systems (T6SSs) are bacterial protein export machines postulated to puncture targeted cells using an apparatus that shares structural similarity to bacteriophage. We investigated the role of the five T6SSs of Burkholderia thailandensis in the defense of the organism against other bacteria and higher organisms. B. thailandensis is a relatively avirulent soil saprophyte that is closely related to the human pathogen, B. pseudomallei. Our work uncovered roles for two B. thailandensis T6SSs with specialized functions in the survival of the organism in a murine host, or against another bacterial cell. We also found that B. thailandensis lacking the bacterial-targeting T6SS could not persist in a mixed biofilm with a competing bacterium. Based on the evolutionary relationship of T6SSs, and our findings that B. thailandensis engages other bacterial species in a T6S-dependent manner, we speculate that this pathway is of general significance to interbacterial interactions in polymicrobial human diseases and the environment.
Bacteria have evolved many mechanisms of defense against competitors and predators in their environment. Some of these, such as type III secretion systems (T3SSs) and bacteriocins, provide specialized protection against eukaryotic or bacterial cells, respectively [1,2]. Gene clusters encoding apparent type VI secretion systems (T6SSs) are widely dispersed in the proteobacteria; however, the general role of these systems in eukaryotic versus bacterial cell interactions is not known [3,4].
To date, most studies of T6S have focused on its role in pathogenesis and host interactions [5,6,7]. In certain instances, compelling evidence for the specialization of T6S in guiding eukaryotic cell interactions has been generated. Most notably, the systems of Vibrio cholerae and Aeromonas hydrophila were shown to translocate proteins with host effector domains into eukaryotic cells [8,9]. Evidence is also emerging that T6SSs could contribute to interactions between bacteria. The Pseudomonas aeruginosa HSI-I-encoded T6SS(H1-T6SS) was shown to target a toxin to other P. aeruginosa cells, but not to eukaryotic cells [10]. Unfortunately, analyses of the ecological niche occupied by bacteria that possess T6S have not been widely informative for classifying their function [3,4]. These efforts are complicated by the fact that pathogenic proteobacteria have environmental reservoirs, where they undoubtedly encounter other bacteria. The observation that many bacteria possess multiple evolutionarily distinct T6S gene clusters-up to seven in one organism-raises the intriguing possibility that each system may function in an organismal or context-specific manner [3].
The T6SS is encoded by approximately 15 core genes and a variable number of non-conserved accessory elements [4]. Data from functional assays and protein localization studies suggest that these proteins assemble into a multi-component secretory apparatus [11,12,13]. The AAA+ family ATPase, ClpV, is one of only a few core proteins of the T6S apparatus that have been characterized. Its ATPase activity is essential for T6S function [14], and it associates with several other conserved T6S proteins [15,16]. ClpV-interacting proteins A and B (VipA and VipB) form tubules that are remodeled by the ATPase, which could indicate a role for the protein in secretion system biogenesis. Two proteins exported by the T6SS are haemolysin co-regulated protein (Hcp) and valine-glycine repeat protein G (VgrG). Secretion of these proteins is co-dependent, and they may be extracellular components of the apparatus [10,13,17,18,19,20].
Burkholderia pseudomallei is an environmental saprophrophyte and the causative agent of melioidosis [21]. Infection with B. pseudomallei typically occurs percutaneously via direct contact with contaminated water or soil, however it can also occur through inhalation. The ecological niche and geographical distribution of B. pseudomallei overlap with a relatively non-pathogenic, but closely related species, Burkholderia thailandensis (B. thai) [22]. The genomes of these bacteria are highly similar in both overall sequence and gene synteny [23,24]. One study estimates that the two microorganisms separated from a common ancestor approximately 47 million years ago [24]. It is postulated that the B. pseudomallei branch then diverged from Burkholderia mallei, which underwent rapid gene loss and decay during its evolution into an obligate zoonotic pathogen [25]. As closely related organisms that represent three extremes of bacterial adaptation, the Burkholderia offer unique insight into the outcomes of different selective pressures on the expression and maintenance of certain traits.
B. pseudomallei possesses a large and complex repertoire of specialized protein secretion systems, including three type III secretion systems (T3SSs) and six evolutionarily distinct T6SSs [3,26,27]. The genomes of B. thailandensis and B. mallei contain unique sets of five of the six B. pseudomallei T6S gene clusters; thus, of the six evolutionarily distinct “Burkholderia T6SSs,” four are conserved among the three species. Remarkably, T6SSs account for over 2% of the coding capacity of the large genomes of these organisms. For the current study, we have adopted the Burkholderia T6SS nomenclature proposed by Thomas and colleagues [28].
To date, only Burkholderia T6SS-5, one of the four conserved systems, has been investigated experimentally. The system was investigated in B. mallei based on its co-regulation with virulence determinants such as actin-based motility and capsule [27]. B. mallei strains lacking a functional T6SS-5 are strongly attenuated in a hamster model of glanders. Preliminary studies suggest that T6SS-5 is also required for B. pseudomallei pathogenesis [28,29]. In one study, a strain bearing a transposon insertion within T6SS-5 was identified in a screen for B. pseudomallei mutants with impaired intercellular spreading in cultured epithelial cells [29]. The authors also showed that this insertion caused significant attenuation in a murine infection model.
Herein, we set out to systematically define the function of the Burkholderia T6SSs. Our study began with the observation that well characterized examples of eukaryotic and bacterial cell-targeting T6SSs segregate into distant subtrees of the T6S phylogeny. We found that Burkholderia T6SS-5 clustered closely with eukaryotic cell-targeting systems, and was the only system in B. thai that was required for virulence in a murine model of pneumonic melioidosis. The remaining systems clustered proximal to a bacterial cell-targeting T6SS in the phylogeny. One of these, T6SS-1, displayed a profound effect on the fitness of B. thai in competition with several bacterial species. The function of T6SS-1 required cell contact and its absence caused sensitivity of the strain to stasis induced by competing bacteria. In flow cell biofilm assays initiated with 1:1 mixtures of B. thai and Pseudomonas putida, wild-type B. thai predominated, whereas the ΔT6SS-1 strain was rapidly displaced by P. putida. Our findings point toward an important role for T6S in interspecies bacterial interactions.
We conducted phylogenetic analyses of all available T6SSs to examine the evolutionary relationship between eukaryotic and bacterial cell-targeting systems. The phylogenetic tree we constructed was based on VipA, as this protein is a highly conserved element of T6SSs that has been demonstrated to physically interact with two other core T6S proteins, including the ClpV ATPase [15]. In the resulting phylogeny, the systems of V. cholerae and A. hydrophila, two well-characterized eukaryotic cell-targeting systems, clustered closely within one of the subtrees, whereas the bacteria-specific P. aeruginosa H1-T6SS was a member of a distant subtree (
Next we examined the locations of the six Burkholderia T6SSs. Interestingly, T6SS-5, the only Burkholderia system previously implicated in virulence, clustered within the substree containing the V. cholerae and A. hydrophila systems (
We chose B. thai as a tractable model organism in which to experimentally investigate the role of the Burkholderia T6SSs. Due to our limited knowledge regarding the function and essentiality of each gene within a given T6SS cluster, we reasoned it prudent to inactivate multiple conserved genes for initial phenotypic studies. Strains lacking the function of each of the five B. thai T6SSs (Burkholderia T6SS-3 is absent in B. thai) were prepared by removing three to five genes, including at least two that are highly conserved (
To probe the role of the Burkholderia T6SSs in virulence, we utilized a recently developed acute pneumonia model of melioidosis [30]. The survival of mice infected with approximately 105 aerosolized wild-type or mutant bacteria was monitored over the course of ten days. Consistent with previous studies implicating T6SS-5 in B. mallei and B. pseudomallei pathogenesis, mice infected with ΔT6SS-5 survived the course and displayed no outward symptoms of the infection (
The B. thai T6SS-5 locus is adjacent to bsa genes, which encode an animal pathogen-like T3SS. Inactivation of the bsa T3SS secretion system also leads to dramatic attenuation of B. thai in the model we utilized [26]. The regulation of these secretion systems appears to be intertwined; a recent study in B. pseudomallei showed that a protein encoded within the bsa cluster strongly activates T6SS-5 of that organism [31]. To rule out the possibility that attenuation of ΔT6SS-5 was attributable to polar effects or changes in regulation of the bsa T3SS, we generated a strain bearing an in-frame deletion of a single gene in the cluster, tssK-5 (
To investigate whether the retention of virulence in the ΔT6SS-1,2,4 and 6 strains could be attributed to either compensatory activity or redundancy, we next constructed a strain bearing inactivating mutations in all four clusters and measured its virulence in mice. Mice infected with this strain succumbed to the infection with similar kinetics to those infected with the wild-type, indicating that T6SS-5 is the only system of B. thai that is required for virulence in this model (
To more closely examine the requirement for T6SS-5 during infection, we monitored B. thai wild-type and ΔtssK-5 c.f.u. in the lung, liver, and spleen at 4, 24, and 48 hrs following inoculation with approximately 105 bacteria by aerosol. At 4 hrs p.i., no differences were observed in c.f.u. recovered from the lung (
Thus far, our findings did not distinguish between a specific role for T6SS-5 in host interactions, such as escaping or manipulating the innate immune system, versus the alternative explanation that T6SS-5 is generally required for growth in host tissue. To discriminate between these possibilities, we compared the virulence of ΔtssK-5 in wild-type mice to a strain with compromised innate immunity, MyD88−/−[32,33]. Mice lacking MyD88 were unable to control the ΔtssK-5 infection and succumbed within 3 days (
T6S Impacts the Fitness of B. thai in Co-Culture with Diverse Bacterial Species
Earlier work by our laboratory has shown that T6S can influence intraspecies bacterial interactions. We showed that the H1-T6SS of P. aeruginosa targets a toxin to other P. aeruginosa cells [10], and that in growth competition assays, toxin-secreting strains are provided fitness advantage relative to strains lacking a specific toxin immunity protein. Based on this information and the locations of the B. thai T6SSs within our phylogeny, we postulated that one or more of these systems could also play a role in interbacterial interactions. Preliminary studies indicated that T6S did not influence interactions between B. thai strains, thus we decided to test the hypothesis that the B. thai T6SSs play a role in interspecies bacterial interactions.
Without information to guide predictions of specificity, we developed a simple and relatively high-throughput semi-quantitative assay to allow screening of a wide range of organisms for sensitivity to the B. thai T6SSs. The design of the assay was based on two key assumptions for T6S-dependent effects—that they are cell contact-dependent and that they impact fitness (as measured by proliferation). To facilitate measurement of T6S-dependent changes in B. thai proliferation in the presence of competing organisms, we engineered constitutive green fluorescent protein expression cassettes into wild-type B. thai and a strain bearing mutations in all five T6SSs (ΔT6S) [34]. Control experiments showed that the lack of T6S function did not impact growth or swimming motility (
We next screened the B. thai strains against 31 species of bacteria. Most of these were Gram-negative proteobacteria (5 α; 3 β; 18 γ), however two Gram-positive phyla were also represented (4 Firmicutes; 1 Actinobacteria). Although we endeavored to screen a large diversity of bacteria, many taxa could not be included due to specific nutrient requirements or an unacceptably slow growth rate under the conditions of the assay (30° C., Luria-Bertani (LB) medium). The outcomes of most competition experiments were independent of the T6SSs of B. thai. T6S-independent outcomes varied; in most instances, B. thai flourished in the presence of the competing organism (
The second group consisted of three γ-proteobacteria, P. putida, P. fluorescens, and S. proteamaculans. The proliferation of B. thai grown in competition with these organisms appeared to be highly dependent on T6S (
The next question we addressed was whether one or more of the individual T6SSs were responsible for the TDC-specific proliferation phenotype of B. thai ΔT6S. To determine this, we inserted a GFP over-expression cassette into our panel of individual B. thai T6SS deletion strains, and performed plate competition assays against the TDCs. In competition with each TDC, ΔT6SS-1 appeared as deficient in proliferation as ΔT6S, whereas the other strains grew similarly to the wild-type (
It remained possible that the effects of T6SS-1 on the fitness of B. thai in competition with other bacteria were either non-specific or unrelated to its putative role as a T6SS. As mentioned earlier, one common observation from detailed studies of T6SSs conducted to date is that its effects require cell contact [8,9,10]. This has been postulated to reflect a conserved mechanism of the apparatus akin to bacteriophage cell puncturing [18]. To address whether the apparent fitness defect of ΔT6SS-1 involves a mechanism consistent with T6S, we probed whether its effects were dependent upon cell contact. A filter (0.2 μm) placed between B. thai and TDC cells abrogated the T6SS-1-dependent growth defect (
We next sought to quantify the magnitude of T6SS-1 effects on B. thai fitness in competition with TDCs. To ensure the specificity of T6SS-1 inactivation in the strains used in these assays, we generated a B. thai strain bearing an in-frame clpV-1 deletion, and a strain in which this deletion was complemented by clpV-1 expression from a neutral site on the chromosome. In plate competition assays, the ΔclpV-1 strain displayed a fitness defect similar to ΔT6SS-1, and clpV-1 expression complemented the phenotype (
T6SS-1 Provides Resistance to P. putida Induced Stasis of B. thai
Three models could explain the T6SS-1-dependent effects we observed on B. thai fitness in competition with the TDCs: (i) T6SS-1 inhibits TDC proliferation, thereby freeing nutrients for B. thai (ii) T6SS-1 prevents TDC inhibition of B. thai growth, or (iii) T6SS-1 performs both of these functions. To distinguish between these possibilities, we compared B. thai and TDC growth rates following inoculation into either mono-culture or competitive cultures on 3% agar plates. Our prior experiments indicated that T6SS-1-dependent effects on B. thai were similar in competition assays with each TDC (
The proliferation defect of B. thai ΔclpV-1 could be attributable to P. putida-induced growth inhibition, cell killing, or a combination of these factors. We reasoned that if killing was involved in the ΔclpV-1 phenotype, the difference in cell death between wild-type and ΔclpV-1 would be most pronounced at approximately 7.5 hrs following inoculation of the competition assays, when wild-type B. thai are rapidly proliferating and ΔclpV-1 cell numbers are not expanding. At this time point, we identified similar numbers of dead cells in wild-type and ΔclpV-1 competitions, suggesting that T6SS-1 inhibits stasis of B. thai induced by P. putida (
T6SS-1 is Required for the Persistence of B. thai in Mixed Biofilms with P. putida
In our plate competition assays, low moisture availability impairs bacterial motility, and artificially enforces close association of B. thai with the TDCs. To determine whether T6SS-1 could provide a fitness advantage for B. thai under conditions more relevant to its natural habitat, i.e., where nutrients are exchanged and dehydration does not drive interbacterial adhesion, we conducted mixed species flow chamber biofilm assays.
Previous studies in E. coli and V. parahaemolyticus have implicated T6S in the inherent capacity of these organisms to form biofilms {Aschtgen, 2008 #224; Enos-Berlage, 2005 #58}. Furthermore, additional T6SSs are activated during biofilm growth or co-regulated with characterized biofilm factors such as exopolysaccharides {Aubert, 2008 #191; Deretic, 1995 #288; Mougous, 2006 #87; Sauer, 2002 #395; Southey-Pillig, 2005 #396}. Thus, prior to performing mixed species assays, we first tested whether inactivation of T6SS-1 influenced the formation of monotypic B. thai biofilms. Wild-type and ΔT6SS-1 strains adhered equally to the substratum and formed indistinguishable monotypic biofilms that reached confluency after four days (
Next we seeded biofilm chambers with 1:1 mixtures of B. thai and P. putida. In mixed biofilms, the B. thai strains again adhered with similar efficiency, however a dramatic difference between the capacity of the strains to persist and proliferate in the presence of P. putida became apparent within 24 hrs (
Our findings suggest that the highly conserved T6S architecture can serve diverse functions. We found T6SSs within B. thai critically involved in two very distinct processes—virulence in a murine infection model and growth in the presence of specific bacteria. The systems involved in these diverse phenotypes, T6SS-5 and T6SS-1, respectively, are distantly related, and cluster phylogenetically with other T6SSs of matching cellular specificity. We were unable to define the function for three of the B. thai T6SSs, however their clustering in the H1-T6SS subtree suggests that they could have a role in interbacterial interactions. These systems may not have been active under the assay conditions we utilized, they might be specific for organisms we did not include in our screen, or their activity may not affect proliferation. Phylogenies have proven to be powerful tools for guiding researchers studying complex protein secretion systems [35,36]. However, determining whether T6S phylogeny holds promise as a general predictor of organismal specificity will require more studies that evaluate the significance of individual systems in both eukaryotic and bacterial cell interactions.
Although B. thai is not generally regarded as a pathogen, our data suggest that Burkholderia T6SS-5 plays a role in host interactions that is conserved between this species and its pathogenic relatives, B. pseudomallei and B. mallei [27,28,29,37]. We postulate that T6SS-5, like many other virulence factors, evolved to target simple eukaryotes in the environment. The benefit T6SS-5 provides the Burkholderia in a mammalian host could have been one factor that allowed B. mallei to transition into an obligate pathogen. Based on our results implicating T6SS-1 exclusively in interbacterial interactions, the role of this system in the lifestyle of B. mallei is more difficult to envisage. Indeed, the cluster encoding T6SS-1 is the most deteriorated of the T6S clusters of B. mallei and is unlikely to function [27]. Of the 13 conserved T6S-associated orthologous genes, 8 of these appear to be deleted in B. mallei T6SS-1, however the remaining T6S clusters of the organism are largely intact (0-3 pseudogenes or absent genes).
Of the 33 organisms screened, the effects of B. thai T6SS-1 were most pronounced in competitions with P. putida, P. fluorescens, and S. proteamaculans. Whether these organisms are physiologically relevant B. thai T6SS-1 targets is not known, however P. putida and P. fluorescens have been isolated from soil in Thailand [38,39], and the capacity of these organisms to form biofilms is well documented [40,41,42]. P. putida and P. fluorescens are recognized biological control agents, suggesting that the rhizosphere could be one habitat where antagonism with B. thai might occur [43]. Notably, we did not observe T6SS-dependent effects on B. thai proliferation in the presence of the five Gram-positive organisms included in our screen. The number and diversity of organisms we tested were too low to ascribe statistical significance to this observation, however it is tempting to speculate that the effects of T6S might be limited to Gram-negative cells. This would not be unexpected given the structural relatedness of T6S apparatus components to the puncturing device of T4 bacteriophage [18,19,20].
We found that T6SS-1 allows B. thai to proliferate in the presence of the TDCs. This surprising and counterintuitive finding raises the question of what inhibits B. thai ΔclpV-1 growth, and is it an intrinsic (derived from B. thai) or extrinsic (derived from the TDC) factor? Our data indicate that the activity or production of this factor manifests in the absence of T6SS-1 function only when a TDC is present and intimate cell contact occurs. If the factor is intrinsic, we postulate that its activity is inappropriately triggered by ΔT6SS-1 in the presence of the TDCs, but that its function serves an adaptive role for wild-type B. thai. For example, under circumstances where it is not advantageous for B. thai to proliferate, such as when it is exposed to particular organisms, antibiotics, or stresses, this factor could initiate dormancy. There is evidence that T6S components can participate in cell-cell recognition in bacteria. Gibbs et al. recently reported the discovery of an “identification of self” (ids) gene cluster within Proteus mirabilis that contains genes homologous to hcp (idsA) and vgrG (idsB) {Gibbs, 2008 #327}. Inactivation of idsB caused a defect in recognition of its parent, resulting in boundary formation between the strains.
If the factor is extrinsic, T6SS-1 might be more appropriately defined as a defensive, rather than an offensive pathway. T6SS-1 could provide defense by either influencing the production of the extrinsic factor within the TDC, such as by repressing expression, or it could provide physical protection against the factor by obstructing or masking its target. If the fitness effect that T6SS-1 provides B. thai depends on a specific offensive pathway present in competing organisms, the presence of this pathway in an organism could be the basis for the apparent specificity we observed in our screen. Future studies must address whether the determinants of T6SS-1 effects are intrinsic, extrinsic, or a combination of the two. The design of our competition screen was limited in this regard; we measured T6SS-1 activity indirectly, and we were able to test only a modest number of species. Understanding the mechanism of action of T6SS-1, for example by identifying its substrates, will provide insight into the specificity of the secretion apparatus.
While it is widely accepted that diffusible factors such as antibiotics, bacteriocins, and quorum sensing molecules are common mediators of dynamics between species of bacteria, an analogous cell contact-dependent pathway has yet to be defined [44]. We found that T6S can provide protection for a bacterium against cell contact-induced growth inhibition caused by other species of bacteria. Given that most organisms that possess T6S gene clusters are either opportunistic pathogens with large environmental reservoirs or strictly environmental organisms, we hypothesize that T6SSs are, in fact, widely utilized in interbacterial interactions. Bacteria-targeting T6SSs may be of great general significance to understanding interactions and competition within bacterial communities in the environment and in polymicrobial infections.
All research involving live animals was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals, and adhered to the principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 1996. All work involving animals was approved by the Institutional Animal Care and Use Committee at the University of Washington.
B. thai E264 and E. coli cloning strains were routinely cultured in Luria-Bertani (LB) broth or on LB agar at 37° C. All bacterial species used in this study are listed in the legend of
B. thai T6SSs were inactivated utilizing a previously described mutagenesis technique based on the suicide plasmid pJRC115 containing a mutated phenylalanine synthetase (pheS) gene for counterselection [45]. Unmarked in-frame deletions of three to five T6SS genes per T6SS gene cluster (at least two of which are core T6SS genes; see
Genetic Complementation of ΔtssK-5 and ΔclpV-1
The conserved T6SS genes tssK-5 (BTH_II0857) and clpV-1 (BTH_I2958) were deleted using the in-frame deletion mutagenesis technique described above. For single copy complementation, the mini-Tn7 system was utilized [34]. For this, the B. thai ribosomal promoter PS12 sequence was cloned into the suicide vector pUC18T-mini-Tn7T-Tp using complementary oligonucleotides to yield pUC18T-mini-Tn7T-Tp-PS12 [47]. The tssK-5 and clpV-1 open reading frames along with 16-20 by upstream were amplified and inserted into pUC18T-mini-Tn7T-Tp-PS12. The resulting plasmids and the Tn7 helper plasmid, pTNS3, were introduced into appropriate deletion strains by electroporation using a previously described protocol [45,47]. Transposition of the Tn7-constructs into the chromosome of B. thai was determined by PCR as described previously[48].
Construction of Fluorescently Labeled B. thai and P. putida
The mini-Tn7 system was utilized to integrate green fluorescent protein (GFP) and cyan fluorescent protein (CFP) expression cassettes into the chromosome of B. thai and P. putida, respectively [48,49]. To construct a mini-Tn7 derivative for constitutive expression of GFP, the GFP cassette was amplified from pQB1-T7-GFP (Quantum Biotechnologies) without the T7 promoter region as previously described and inserted into KpnI and StuI sites of pUC18T-mini-Tn7T-Tp-PS12 [27]. This plasmid was then introduced into relevant B. thai strains and insertion of Tn7-GFP into the chromosome was verified as described above. To construct a GFP labeled ΔclpV-1 comp strain we made use of the fact that two Tn7 insertion sites (attTn7) are present in the genome of B. thai. The chromosomally integrated Tn7 Tpr resistance cassette of ΔclpV-1 comp was excised using pFLPe2 which expresses a Flp recombinase (Choi, 2008) before introducing pUC18T-mini-Tn7T-Tp-PS12-GFP. Insertion of Tn7-GFP into the other attTn7 site was confirmed by PCR as described previously [48,49]. To engineer CFP labeled P. putida, the mini-Tn7(Gm)-CFP plasmid and the helper plasmid pUX-BF13 were introduced into the strain by electroporation as previously described [49].
Growth kinetics of B. thai strains were measured in LB broth using the automated BioScreen C Microbiology plate reader (Growth Curves) with agitation at 37° C. Three independent measurements were performed in triplicate for each strain.
Swimming motility of B. thai strains was analyzed in 0.25% LB agar. Swimming plates were stab-inoculated with overnight cultures and incubated at 37° C. for 48 h. Two independent experiments were performed.
Murine infection model. Specific-pathogen-free C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, Me.). MyD88−/− mice were derived by Dr. Shizuo Akira (University of Osaka) and backcrossed for at least 8 generations to C57BL/6 [50]. Mice were housed in laminar flow cages with ad lib access to sterile food and water. The Institutional Animal Care and Use Committee of the University of Washington approved all experimental procedures. For aerosol infection of mice, bacteria were grown in LB broth at 37° C. for 18 hours, isolated by centrifugation, washed twice, and suspended in Dulbecco's PBS to the desired concentration. An optical density of 0.20 at 600 nm yielded approximately 1×108 CFU/ml. Mice were exposed to aerosolized bacteria using a nose-only inhalation system (In-Tox Products, Moriarty, N. Mex.) (West, Trans R Soc Trop Med Hyg, 2008). Aerosols were generated from a MiniHEART hi-flo nebulizer (Westmed, Tucson, Ariz.) driven at 40 psi. Airflow through the system was maintained for 10 minutes at 24 l/min followed by five minutes purge with air. Immediately following aerosolization, the pulmonary bacterial deposition was determined by quantitative culture of left lung tissue from three to four sentinel mice. Following infection, animals were monitored one to three times daily for illness or death. Ill animals meeting defined clinical endpoints were euthanized. At specific time points after infection, mice were euthanized in order to quantify bacterial burdens and inflammatory responses. To determine bacterial loads, the left pulmonary hilum was tied off and the left lung, median hepatic lobe, and spleen each were removed and homogenized in 1 ml sterile Dulbecco's PBS. Serial dilutions were plated on LB agar and colonies were counted after 2-4 days of incubation at 37° C. in humid air under 5% CO2.
Overnight cultures of B. thai and competitor bacteria were adjusted to an OD600 nm of 0.1 and mixed 5:1 (v/v). For competitions using fluorescent strains, 2.5 μl of the mixture was spotted on 3% w/v LB agar and fluorescence was measured after approximately one week following incubation at 30° C. For quantitative competitions using non-fluorescent strains, 10 μl of the mixture was spotted on a filter (0.22 μm; GE Water & Process Technologies) and cells were harvested and enumerated at the indicated time points. Colonies of the competing organisms were distinguished from B. thai strains using a combination of colony morphology, growth rate and inherent antibiotic susceptibility.
Growth competitions of B. thai against P. putida were performed on filters as described above. At 7.5 h after initiating the experiment, the filters were resuspended in 200 μl LB broth and cell viability was measured using the LIVE/DEAD BacLight Bacterial Viability Kit for microscopy according to the manufacturer's protocol (Invitrogen). The number of dead cells was determined for five random fields per competition using fluorescence microscopy. Two independent experiments were performed in duplicate.
Biofilms were grown at 25° C. in three-channel flow-chambers (channel dimensions of 1×4×40 mm) irrigated with FAB medium supplemented with 0.3 mM glucose. Flow-chamber biofilm systems were assembled and prepared as previously described [51]. The substratum consisted of a 24×50 mm microscope glass cover slip. Overnight cultures of the relevant strains were diluted to a final OD600nm of 0.01 in 0.9% NaCl, and 300 μl of the diluted bacterial cultures, or 1:1 mixtures, were inoculated by injection into the flow chambers. After inoculation, the flow chambers were allowed to stand inverted without flow for 1 h, after which medium flow was started with flow chambers standing upright. A peristaltic pump (Watson-Marlow 250S) was used to keep the medium flow at a constant velocity of 0.2 mm/s in the flow-chamber channels. Microscopic observation and image acquisition of the biofilms were performed with a Leica TCS-SP5 confocal laser scanning microscope (CLSM) (Leica Microsystems, Germany) equipped with lasers, detectors and filter sets for monitoring GFP and CFP fluorescence. Images were obtained using a 63×/1.4 objective. Image top-down views were generated using the IMARIS software package (Bitplane AG). The flow-chamber experiment reported here was repeated twice, and in each experiment each mono-strain or mixed-strain biofilm was grown in at least two channels, and at least 6 CLSM images were recorded per channel at random positions. Each individual image presented here is therefore representative of at least 24 images.
Annotated genomes were downloaded from the Genome Reviews ftp site (ftp://ftp.ebi.ac.uk/pub/databases/genome_reviews/, January 2010, 926 bacterial genomes (1814 chromosomes and plasmids) [52]. Protein sequences from all genomes were aligned with rpsblast [53] against the COG section of the CDD database (January 2010) [54]. Only proteins showing an alignment covering at least 30% of the COG PSSM with an E-value≦10−6 were retained. To avoid any errors in COG assignments, we discarded all hits that overlap with another hit with a better E-value on more than 50% of its length. We considered the following 13 COGs as ‘T6SS core components’: COG0542, COG3157, COG3455, COG3501, COG3515, COG3516, COG3517, COG3518, COG3519, COG3520, COG3521, COG3522, COG3523 [3,4]. Two genes were considered neighbours if they are separated by less than 5000 bp. Only clusters containing the VipA protein (COG3516) and genes encoding for at least five other T6SS core components were included in the analyses. The Edwardsiella tarda (EMBL access AY424360) system was added manually because the complete genome sequence and annotation of this organism was unavailable in Genome Reviews.
In three of the 334 T6SS clusters, two VipA coding genes were identified. Manual inspection of two of these clusters in Acinetobacter baumannii (ATCC 17978) and Vibrio cholerae (ATCC 39541) revealed that they resulted from apparent gene fissions; in both cases we kept the longest fragment corresponding to the C-terminal part of the full length protein. In the third case, Psychromonas ingrahamii (strain 37), the two VipA coding genes resulted from an apparent duplication event: one of the two copies showed a high mutation frequency and was discarded. In total, we included 334 VipA orthologs in T6SS clusters. The 334 VipA protein sequences were aligned using muscle [55]. Based on this alignment, a neighbour-joining tree with 100 bootstrap replicates was computed using BioNJ [56].
A fosmid (commercial fosmid—pCC2FOS) containing a large fragment of the P. aeruginosa chromosome containing PA0066-PA0094 (PA0095 present, but truncated), which includes all known essential structure genes of the H1-T6SS, was transferred into E. coli SW102 for recombineering (see http://web.ncifcrf.gov/research/brb/recombineeringInformation.aspx). To obtain inducible expression of the system, the native outward facing promoters of HSI-I (region between PA0082 and PA0082) were replaced with T7 promoters. This modified plasmid was placed in E. coli BL21 DE3, wherein T7 polymerase is expression can be induced by IPTG. Based on Western blot experiments demonstrating the presence of an α-Hcp1 (PA0085)-reactive band present only in induced samples bearing the HSI-I-encoding plasmid (data not shown), we concluded that successful inducible expression of secretion system components was obtained.
Heterologous expression of periplasmic-targeted Tse1 and Tse3 in E. coli (see
Pseudomonas aeruginosa PAO1 wild-type and indicated mutants and Pseudomonas putida KT2440 were grown overnight at 37° C. and 30° C. respectively in LB shaking cultures. These cultures were then diluted to an OD of 2.5 before being mixed 1:10 aeruginosa:putida. These mixtures were then diluted 1:10 in LB and 10 μl spots were placed on nitrocellulose membrane on top of LB plates with 3% agar and no salt. These spots were then incubated at 30° C. for 24 hours. Dilutions were also taken of the original mixture and plated on LB and incubated overnight to obtain an initial inoculum ratio. At the end of the 24 hour incubation cells were scrapped off the nitrocellulose membranes into 200 μl LB, and dilutions were plated of this mixture and incubated at 30° C. to determine the final ratio of aeruginosa:putida. In order to obtain the relative increase in ratio, the final ratio was divided by the initial ratio. The conclusion from this study is that Tse1 and Tse3 are toxin to another bacterium when delivered via the T6SS (though toxicity is indirectly read out through increased fitness of the donor bacterium). This data also suggests that the H1-T6SS, which exports Tse1-3, can target bacteria other than P. aeruginosa.
This application claims priority to U.S. Provisional Patent Application Ser. No. 61/286,899 filed Dec. 16, 2009, which is incorporated by reference herein in its entirety.
This work was funded in part by NIH Grant Nos. AI080609 and AI057141. The U.S. government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 61286899 | Dec 2009 | US |
